WO2013035345A2 - Dengue-virus serotype neutralizing antibodies - Google Patents
Dengue-virus serotype neutralizing antibodies Download PDFInfo
- Publication number
- WO2013035345A2 WO2013035345A2 PCT/JP2012/005699 JP2012005699W WO2013035345A2 WO 2013035345 A2 WO2013035345 A2 WO 2013035345A2 JP 2012005699 W JP2012005699 W JP 2012005699W WO 2013035345 A2 WO2013035345 A2 WO 2013035345A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- cdr
- cdr2
- cdr3
- cdr1
- Prior art date
Links
- 241000725619 Dengue virus Species 0.000 title claims abstract description 169
- 230000003472 neutralizing effect Effects 0.000 title description 24
- 208000015181 infectious disease Diseases 0.000 claims abstract description 60
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 292
- 210000004027 cell Anatomy 0.000 claims description 112
- 210000004408 hybridoma Anatomy 0.000 claims description 96
- 230000000694 effects Effects 0.000 claims description 66
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 59
- 238000006386 neutralization reaction Methods 0.000 claims description 41
- 230000001154 acute effect Effects 0.000 claims description 40
- 239000000427 antigen Substances 0.000 claims description 39
- 108091007433 antigens Proteins 0.000 claims description 39
- 102000036639 antigens Human genes 0.000 claims description 39
- 239000012634 fragment Substances 0.000 claims description 39
- 230000027455 binding Effects 0.000 claims description 37
- 230000004927 fusion Effects 0.000 claims description 32
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 18
- 230000007910 cell fusion Effects 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 64
- 206010012310 Dengue fever Diseases 0.000 abstract description 94
- 208000025729 dengue disease Diseases 0.000 abstract description 76
- 208000001490 Dengue Diseases 0.000 abstract description 75
- 238000000034 method Methods 0.000 abstract description 45
- 239000000463 material Substances 0.000 abstract description 12
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 abstract description 2
- 150000001413 amino acids Chemical group 0.000 description 135
- 238000003556 assay Methods 0.000 description 104
- 238000010166 immunofluorescence Methods 0.000 description 80
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 31
- 239000002953 phosphate buffered saline Substances 0.000 description 31
- 208000009714 Severe Dengue Diseases 0.000 description 30
- 239000000203 mixture Substances 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- 239000003814 drug Substances 0.000 description 27
- 210000003501 vero cell Anatomy 0.000 description 27
- 206010037660 Pyrexia Diseases 0.000 description 25
- 238000010790 dilution Methods 0.000 description 23
- 239000012895 dilution Substances 0.000 description 23
- 230000009260 cross reactivity Effects 0.000 description 22
- 239000012531 culture fluid Substances 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 19
- 238000009472 formulation Methods 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 18
- 239000012091 fetal bovine serum Substances 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 210000003719 b-lymphocyte Anatomy 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 17
- 101710158312 DNA-binding protein HU-beta Proteins 0.000 description 16
- -1 F(ab')2 Proteins 0.000 description 16
- 101710128560 Initiator protein NS1 Proteins 0.000 description 16
- 101710144127 Non-structural protein 1 Proteins 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 230000009467 reduction Effects 0.000 description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- 239000013642 negative control Substances 0.000 description 15
- 229940124597 therapeutic agent Drugs 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000012530 fluid Substances 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- 208000032843 Hemorrhage Diseases 0.000 description 12
- 241001529936 Murinae Species 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 239000002502 liposome Substances 0.000 description 12
- 208000003322 Coinfection Diseases 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 241000710842 Japanese encephalitis virus Species 0.000 description 10
- 201000009892 dengue shock syndrome Diseases 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000009257 reactivity Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 102100034349 Integrase Human genes 0.000 description 9
- 108010067390 Viral Proteins Proteins 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 101710204837 Envelope small membrane protein Proteins 0.000 description 8
- 101710145006 Lysis protein Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 230000035939 shock Effects 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 7
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000003086 colorant Substances 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 206010022000 influenza Diseases 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 230000009103 reabsorption Effects 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000003441 anti-flavivirus Effects 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 241000712461 unidentified influenza virus Species 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000001806 memory b lymphocyte Anatomy 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 101710120037 Toxin CcdB Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010370 cell cloning Methods 0.000 description 4
- 230000037029 cross reaction Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000012103 Alexa Fluor 488 Substances 0.000 description 3
- 101710117545 C protein Proteins 0.000 description 3
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 208000034657 Convalescence Diseases 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 241000255925 Diptera Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 206010058874 Viraemia Diseases 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000001932 seasonal effect Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000710829 Dengue virus group Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 101150013191 E gene Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000032163 Emerging Communicable disease Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010016803 Fluid overload Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010021137 Hypovolaemia Diseases 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000012574 advanced DMEM Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N citrulline Chemical compound OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 2
- 229960002173 citrulline Drugs 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229940124452 immunizing agent Drugs 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 241001515942 marmosets Species 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000001293 nucleolytic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 239000008180 pharmaceutical surfactant Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 210000003281 pleural cavity Anatomy 0.000 description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 230000035485 pulse pressure Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MOQVHOPVBREXLY-UHFFFAOYSA-N 3h-dioxol-4-ylmethanol Chemical compound OCC1=COOC1 MOQVHOPVBREXLY-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- AFZIRBOYYNKYFJ-UHFFFAOYSA-N 4-pyridin-2-ylsulfanylpentanoic acid Chemical compound OC(=O)CCC(C)SC1=CC=CC=N1 AFZIRBOYYNKYFJ-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 241000256111 Aedes <genus> Species 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010020961 Hypocholesterolaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100174574 Mus musculus Pikfyve gene Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
- 101150033828 NS1 gene Proteins 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 238000010806 PrimeScriptTM RT Reagent kit Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010037868 Rash maculo-papular Diseases 0.000 description 1
- 230000010757 Reduction Activity Effects 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102100035254 Sodium- and chloride-dependent GABA transporter 3 Human genes 0.000 description 1
- 101710104417 Sodium- and chloride-dependent GABA transporter 3 Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000710888 St. Louis encephalitis virus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 241001529801 Tick-borne flavivirus Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 206010050058 Urogenital haemorrhage Diseases 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000454 anti-cipatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229930191339 dianthin Natural products 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 210000001983 hard palate Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000012965 maculopapular rash Diseases 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108010010621 modeccin Proteins 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000037972 tropical disease Diseases 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present invention relates to materials and methods for the treatment of dengue viral infections.
- the present invention relates to an anti dengue virus (DENV) monoclonal antibody or an antigen-binding fragment thereof, the monoclonal antibody or the antigen-binding fragment thereof comprising a neutralization activity against serotypes of DENV-1, DENV-2, DENV-3 and DENV-4, wherein the monoclonal antibody comprises a human monoclonal antibody or a humanized monoclonal antibody.
- DENV dengue virus
- JST Japan Science and Technology Agency
- JICA Japan International Cooperation Agency
- SATREPS Science and Technology Research Partnership for Sustainable Development
- DENV-1 to DENV-4 dengue virus serotypes
- ADE antibody-dependent enhancement
- pre-existing memory cells producing specific antibodies could play a significant role in quickly providing neutralizing antibodies to protect against the current virus infection.
- DENV pre-existing neutralizing antibodies raised by the primary infection are protective against infection with the same DENV serotype. Severe dengue cases may mostly occur among patients secondarily infected with different DENV serotypes. This may be due to antibody-dependent enhancement (ADE), where part of the pre-existing anti-DENV antibodies raised by the primary DENV infection, by which the current infecting virus can be amplified in Fc receptor-positive macrophages.
- ADE antibody-dependent enhancement
- DENV infections may be asymptomatic, even among individuals secondarily infected with heterotypic DENV. Some of these cases may show a wide spectrum of clinical symptoms, from a mild dengue fever to severe dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Harris et al., Am. J. Trop. Med. Hyg. 63:5-11(2000).
- DHF dengue hemorrhagic fever
- DSS dengue shock syndrome
- HuMAbs are increasingly used in the treatment of cancer, and more recently, infectious diseases (Reichert et al., Nat. Biotechnol. 23:1073-1078 (2005)), such as RS virus (Frogel et al., J. Manag. Care Pharm. 16:46-58 (2010); Mansbach et al., Pediatr Emerg Care 23: 362-367 (2007)).
- HuMAbs can be produced by the immortalization of B cells with Epstein-Barr virus (EBV) (Kozbor, J. Immunol., 127:1275-1280 (1981); Steinitz et al., J. Immunol., 141: 3516-3522 (1988); Lanzavecchia et al., Curr.
- EBV Epstein-Barr virus
- HuMAbs were prepared against seasonal influenza A viruses, H1N1 and H3N2, by fusion of PBMC from influenza-vaccinated volunteers with newly developed murine-human chimera fusion partner cells, named SPYMEG (Kubota-Koketsu et al., Biochem. Biophys. Res. Commun., 387:180-185 (2009)).
- HuMAbs Preparing HuMAbs through the immortalization of patient-derived B cells with EBV method, Dejnirattisai et al. (Science 328:745-748 (2010)) prepared anti-E and anti-prM HuMAbs using B cells from DENV-infected 7 patients on 15-24 days after defervescence. They also observed that 89% of anti-E HuMAbs were complex-type. However, they prepared more anti-prM than anti-E HuMAbs. The anti-prM HuMAbs were also highly cross-reactive with all 4 serotypes of DENV (94%) and potently promoted ADE.
- Bettramello et al. (Cell. Host. Microbe, 8:271-283 (2010)) used B cells from three primarily infected patients after 200 days to 8 or more years after infection and from two secondarily infected patients at 212 to 510 days after infection. Because the domain III of the E protein is the main target of neutralizing anti-flavivirus in mice (Oliphant et al., "J. Virol. 81:11828-11839 (2007).), they also performed a large screen to gain insights into a domain specificity and cross-reactivity of E domain III-specific antibodies isolated from 2 patients, one with a primary infection (donor 13) and the other with a secondary infection (donor 12).
- Wrammert et al. found that rapid and robust influenza-specific IgG+ antibody-secreting plasma cells at peak levels approximately 7 days after vaccination. Those cells accounted for up to 6% of the peripheral blood B cells. However, influenza-specific IgG+ memory B cells at peak levels 14-21 days after vaccination, which accounted for average of 1% of all B cells. Generally, reports show a difference in the B cell phenotype between acute- and convalescent-phase patients of infectious diseases (Leyendeckers et al., Eur. J. Immunol. 29:1406-1417 (1999)). Schieffelin et al. (Virol. J. 7:28 (2010)) obtained complex-type human MAbs have been previously obtained.
- Human monoclonal antibody that shows strong neutralization to all serotypes (complex-type) .
- the present invention provides for the efficient preparation of hybridomas producing HuMAbs against DENV, using peripheral blood mononuclear cells (PBMCs) from patients with secondary infections.
- PBMCs peripheral blood mononuclear cells
- Hybridoma clones were efficiently prepared that produce robust HuMAb using the PBMCs from infant patients at acute phase of infection (around 1 week after the onset of illness).
- HuMAbs that neutralize all 4 serotypes of DENV were obtained efficiently when PBMCs from acute-phase patients were used, with 57.9% (70/121) from acute and only 6.7% (1/15) from convalescent phase. They showed 50% or more reduction in the proliferation of all 4 DENV serotypes.
- the secondary virus infection can play a significant role as a boost stimulation of the memory cells, to transiently increase the number of antibody-secreting plasma cells in patients in the early phase of infection.
- the 4 DENV serotypes are partially cross-reactive with each other; it is believed that this is related to the mechanism that induces severe cases of dengue in secondarily infected patients, antibody-dependent enhancement (ADE).
- ADE antibody-dependent enhancement
- PBMCs were sampled from patients with dengue infection, to prepare hybridomas producing neutralizing HuMAbs against all DENV serotypes.
- efficiency of obtaining neutralizing HuMAbs with PBMCs from patients in the acute and convalescent phases was compared, it was found that efficiency was much greater in the acute phase, although there was a slight tendency towards higher neutralizing antibody titers in plasma from the convalescent than acute phase.
- the HuMAbs described herein are useful for characterizing the molecular mechanisms to induce pathogenicity, including ADE in dengue infection, and for the identification of promising candidates for antibody therapeutics.
- Another feature of the present invention is to provide human monoclonal antibodies against all serotypes of dengue virus.
- a further feature of the present invention is to use human monoclonal antibodies to neutralize all dengue-virus serotypes using patients' peripheral blood lymphocytes.
- the present invention relates to a 1.
- An anti dengue virus (DENV) monoclonal antibody or an antigen-binding fragment thereof the monoclonal antibody or the antigen-binding fragment thereof comprising a neutralization activity against serotypes of DENV-1, DENV-2, DENV-3 and DENV-4, wherein the monoclonal antibody comprises a human monoclonal antibody or a humanized monoclonal antibody.
- DENV dengue virus
- An antiDENV human monoclonal antibody according to item 1 wherein the human monoclonal antibody is produced by a hybridoma made by fusing a peripheral blood mononuclear cell (PBMC) from a patient in an acute phase of DENV infection with a fusion partner cell capable of efficient cell fusion.
- PBMC peripheral blood mononuclear cell
- the antiDENV human monoclonal antibody according to item 2 wherein the fusion partner cell is a SPYMEG cell.
- the anti-DENV monoclonal antibody or antigen-binding fragment thereof according to item 1 comprising an IgG, a Fab, a Fab', a F(ab')2, a scFv, or a dsFv. 5.
- An antidengue virus(DENV) monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region any one of (a) to (gg): (a)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:1 of CDR1, SEQ ID NO:2 of CDR2, and SEQ ID NO:3 of CDR3; and a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:100 of CDR1, SEQ ID NO:101 of CDR2, and SEQ ID NO:102 of CDR3; (b)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:4 of CDR1, SEQ ID NO:5 of CDR2, and SEQ ID NO:6 of CDR3; and a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:103 of CDR1, SEQ
- the antiDENV human monoclonal antibody according to item 5 comprising an IgG, a Fab, a Fab', a F(ab')2, a scFv, or a dsFv.
- a method for producing an antidengue virus (DENV) human monoclonal antibody comprising: 1)producing a hybridoma by fusing a peripheral blood mononuclear cell (PBMC) from a patient in an acute phase of DENV infection with a fusion partner cell capable of efficient cell fusion; 2)obtaining an anti-DENV human monoclonal antibody from the hybridoma.
- PBMC peripheral blood mononuclear cell
- the fusion partner cell is a SPYMEG cell.
- a method for producing a hybridoma comprising fusing a peripheral blood mononuclear cell (PBMC) from a patient in an acute phase of dengue virus (DENV) infection with a fusion partner cell capable of efficient cell fusion.
- PBMC peripheral blood mononuclear cell
- DEV dengue virus
- a fusion partner cell capable of efficient cell fusion.
- the fusion partner cell is a SPYMEG cell.
- an antiDENV human monoclonal antibody obtained from the hybridoma comprises a neutralization activity against serotypes of DENV-1, DENV-2, DENV-3 and DENV-4.
- FIG. 1 illustrates summary of HuMAbs and their cross-reactivity to DENV-1 to -4 in IF and VN assays.
- a total of 121 acute-phase HuMAbs and 15 convalescent-phase HuMAbs were examined for cross-reactivity and cross-neutralization against DENV serotypes in IF and VN assays, respectively.
- Culture fluids of HuMAb-producing hybridoma clones were used.
- the HuMAbs were classified as groups 1 to 10 and groups A to X according to their cross-reactivity against the four serotypes of DENV in IF assay and VN assay, respectively. Individual groups are shown by different colors. Vero cells individually infected with DENV-1 to -4 were used as target cells in these assays.
- FIG. 2 illustrates representation of the percentages of HuMAbs obtained from individual patients for their cross-reactivity with DENV-1 to -4 by IF and VN assays.
- a total of 121 acute-phase HuMAbs 75 from D23, 25 from D30, five from D32, and 16 from D33
- 15 convalescent-phase HuMAbs four from D22, five from D25, two from D26, two from D27, and two from D28) were examined for their cross-reactivity and cross-neutralization against four serotypes of DENV.
- FIG. 3 shows staining profiles of HuMAbs by IF assay.
- the HuMAbs in the culture fluids of hybridoma clones producing DENV serotype-specific (D28-2B11D10 in group 1 and D23-4A7D6 in group 2), cross-reactive with two serotypes (D28-2B11F9 in group 3 and D23-1B11A5 in group 4), and cross-reactive with three serotypes (D25-4D3D2 in group 7 and D23-3E6D7 in group 8), and cross-reactive with all four serotypes (D22-1B7G2 in group 10) antibodies were used for IF. Vero cells mock-infected with PBS or individually infected with DENV-1 to -4 were used as target cells.
- FIG. 4 shows a correlation between IF and VN results.
- a total of 121 acute-phase HuMAbs and 15 convalescent-phase HuMAbs are shown separately to highlight the correlation between IF and VN ("-", ⁇ 50%; "+”, 50% to ⁇ 90%; and “++", 90% neutralization) according to their cross-reactivity with different DENV serotypes (groups 1 to 10 according to the IF assay and groups A to X according to the VN assay).
- Culture fluids of HuMAb-producing hybridoma clones were used. Individual groups are shown by different colors, as in Figure 1.
- FIG. 5 shows binding limits of 18 HuMAbs to four serotypes of DENV by indirect IF assay. Vero cells in 96-well microplate were infected with DENV. After incubation for 2 days, the cells were fixed with formaldehyde, then reacted with the serial 10-fold dilutions of the purified individual HuMAbs (10.0 micrograms/ml). As the titer for the reactivity to individual serotypes of DENV by indirect IF assay, the final antibody concentration showing positive reaction is shown in figure.
- FIG. 6 shows VN activity of 18 HuMAbs to four serotypes of DENV.
- FIGs. 7 show VN and ADE activities of 18 HuMAbs to DENV-2.
- Vero cells were infected with DENV2 (16681 strain) which had been incubated with serial 2-fold dilutions of the purified HuMAbs (25.0 micrograms/ml) at 37 centigrade for 30 min, and incubated at 37 centigrade for overnight. Finally, the cells were fixed and infected cells were detected by IF assay with 4G2.
- THP-1 cells were infected with DENV-2 (16681 strain) which had been incubated with serial 10-fold dilutions of the purified HuMAbs (10.0 micrograms/ml) at 37 centigrade for 30 min, then incubated for 3 days.
- FIG. 7-1 shows 4G2, 5E4, D23-1A10H7 and D23-1B3B9.
- FIG. 7-2 shows D23-1C2D2, D23-1G7C2, D23-1H5A11 and D23-3A10G2.
- FIG. 7-3 shows D23-4A6F9, D23-4F5E1, D23-4H12C8 and D23-5E6B1.
- FIG. 7-4 shows D23-5G2D2, D23-5G8E3, D23-1C1G4 and D30-1E7B8.
- FIG. 7-5 shows D30-3A1E2, D30-33B6C7, D32-2D1G5 and D32-2H8G1.
- FIG.8 shows ADE activities of representative two HuMAbs to four serotypes of DENV.
- four serotypes of DENV (Mochizuki strain of DENV-1; 16681 strain of DENV-2; H87 strain of DENV-3; and H241 strain of DENV-4) were used as in Fig. 7. The infection was performed at an MOI of 0.05.
- FIG.9 shows IF binding activity of representative HuMAbs to clinical isolates of DENV.
- FIG.10 shows VN activity of representative HuMAbs to clinical isolates of DENV.
- Representative HuMAbs, D23-1A10H7, D23-1B3B9, and D23-1G7C2 were examined for VN50 assay to clinical isolates DV1-1 to DV1-5, DV2-1 to DV2-5, DV3-1 to DV3-5, and DV4-1 to DV4-5.
- FIG.11 shows the results of in vivo therapeutic efficiency of HuMAbs in suckling mice.
- FIG.12 shows examples of the pictures of Immunofluorescent assay of positive control, negative control, Hybridoma clones DMSc-17, DMSc-14 and DMSc-36.
- FIG.13 shows illustration of 22 clones showing VN reduction to DENV1, DENV2, DENV3, DENV4 higher than 80%. All clones showed VN to DENV1 and DENV2 higher than 90%. The 10 clones showed VN to DENV3 and 16 clones showed VN to DENV4 higher than 90%.
- the present invention provides antibodies against dengue and methods of using the same to treat a dengue infection.
- An anti dengue virus (DENV) monoclonal antibody or an antigen-binding fragment thereof comprising a neutralization activity against serotypes of DENV-1, DENV-2, DENV-3 and DENV-4, wherein the monoclonal antibody comprises a human monoclonal antibody or a humanized monoclonal antibody.
- PBMC peripheral blood mononuclear cell
- the antiDENV human monoclonal antibody according to item 2 wherein the fusion partner cell is a SPYMEG cell. 4.
- the anti-DENV monoclonal antibody or antigen-binding fragment thereof according to item 1 comprising an IgG, a Fab, a Fab', a F(ab')2, a scFv, or a dsFv. 5.
- An antidengue virus(DENV) monoclonal antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region any one of (a) to (gg): (a)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:1 of CDR1, SEQ ID NO:2 of CDR2, and SEQ ID NO:3 of CDR3; and a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:100 of CDR1, SEQ ID NO:101 of CDR2, and SEQ ID NO:102 of CDR3; (b)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:4 of CDR1, SEQ ID NO:5 of CDR2, and SEQ ID NO:6 of CDR3; and a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:103 of CDR1, SEQ
- the antiDENV human monoclonal antibody according to item 5 comprising an IgG, a Fab, a Fab', a F(ab')2, a scFv, or a dsFv.
- a method for producing an antidengue virus (DENV) human monoclonal antibody comprising: 1)producing a hybridoma by fusing a peripheral blood mononuclear cell (PBMC) from a patient in an acute phase of DENV infection with a fusion partner cell capable of efficient cell fusion; 2)obtaining an anti-DENV human monoclonal antibody from the hybridoma.
- PBMC peripheral blood mononuclear cell
- the fusion partner cell is a SPYMEG cell.
- a method for producing a hybridoma comprising fusing a peripheral blood mononuclear cell (PBMC) from a patient in an acute phase of dengue virus (DENV) infection with a fusion partner cell capable of efficient cell fusion.
- PBMC peripheral blood mononuclear cell
- DEV dengue virus
- a fusion partner cell capable of efficient cell fusion.
- the fusion partner cell is a SPYMEG cell.
- an antiDENV human monoclonal antibody obtained from the hybridoma comprises a neutralization activity against serotypes of DENV-1, DENV-2, DENV-3 and DENV-4.
- Anti-dengue antibodies and polypeptides containing antigen binding fragments thereof are provided as well as methods, uses, compositions, and kits employing the same.
- a method of forming an antibody specific to a dengue or a polypeptide or a fragment thereof is provided. Such a method can contain providing a nucleic acid encoding a dengue antigen polypeptide or a polypeptide containing an immunologically specific epitope thereof; expressing the polypeptide containing the antigen amino acid sequence or a polypeptide containing an immunologically specific epitope thereof from the isolated nucleic acid; and generating an antibody specific to the polypeptide obtained or a polypeptide containing an antigen binding fragment thereof.
- An antibody or polypeptide containing an antigen binding fragment thereof produced by the aforementioned method is provided.
- An isolated antibody or isolated polypeptide containing an antigen binding fragment thereof that specifically binds a dengue antigen is provided.
- Such an antibody can be generated using any acceptable method(s) known in the art.
- the antibodies as well as kits, methods, and/or other aspects of the present invention employing antibodies can include one or more of the following: a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single-chain antibody, a monovalent antibody, a diabody, and/or a humanized antibody.
- Naturally occurring antibody structural units typically contain a tetramer.
- Each such tetramer can be composed of two identical pairs of polypeptide chains, each pair having one full-length light" (for example, about 25 kDa) and one full- length "heavy" chain (for example, about 50-70 kDa).
- the amino-terminal portion of each chain typically includes a variable region of about 100 to 110 or more amino acids that typically is responsible for antigen recognition.
- the carboxy-terminal portion of each chain typically defines a constant region that may be responsible for effector function.
- Human light chains are typically classified as kappa and lambda light chains.
- Heavy chains are typically classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively.
- IgG has several subclasses, including, but not limited to, IgGl, IgG2, IgG3, and IgG4.
- IgM has subclasses including, but not limited to, IgMl and IgM2.
- IgA is similarly subdivided into subclasses including, but not limited to, IgAl and IgA2.
- variable and constant regions can be joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D” region of about 10 or more amino acids.
- J Fundamental Immunology Ch. 7
- D variable region of about 10 or more amino acids.
- variable regions typically exhibit the same general structure of relatively conserved framework regions (FR) joined by three hyper variable regions, also called complementarity determining regions or CDRs.
- the CDRs from the two chains of each pair typically are aligned by the framework regions, which can enable binding to a specific epitope.
- both light and heavy chain variable regions typically contain the domains FRl, CDRl, FR2, CDR2, FR3, CDR3 and FR4.
- the assignment of amino acids to each domain is typically in accordance with the definitions of Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk J. MoI. Biol. 196:901-917 (1987); Chothia et al., Nature 342:878-883 (1989).
- Antibody fragments include a portion of an intact antibody, such as the antigen binding or variable region of the intact antibody.
- antibody fragments include Fab, Fab1, F(ab')2, and Fv fragments; diabodies; linear antibodies (Zapata et al., Protein Eng. 8(10): 1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
- Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual "Fc” fragment, a designation reflecting the ability to crystallize readily.
- Fv is an antibody fragment which contains a complete antigen-recognition and -binding site. This region includes a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. A single variable domain (or half of an Fv containing only three CDRs specific for an antigen) can recognize and bind an antigen.
- Single-chain Fv or “sFv” antibody fragments include the VH and VL domains of the antibody, wherein these domains are present in a single polypeptide chain.
- the Fv polypeptide can further contain a polypeptide linker between the VH and VL domains which enables the sFv to form the desired structure for antigen binding.
- a polypeptide linker between the VH and VL domains which enables the sFv to form the desired structure for antigen binding.
- Antibodies can be used as probes, therapeutic treatments and other uses. Antibodies can be made by injecting mice, rabbits, goats, or other animals with the translated product or synthetic peptide fragments thereof. These antibodies are useful in diagnostic assays or as an active ingredient in a pharmaceutical composition.
- the antibody or polypeptide administered can be conjugated to a functional agent to form an immunoconjugate.
- the functional agent can be a cytotoxic agent such as a chemotherapeutic agent, a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate), an antibiotic, a nucleolytic enzyme, or any combination thereof.
- Chemotherapeutic agents can be used in the generation of immunoconjugates, e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents, enzymes, and/or fragments thereof, such as nucleolytic enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof, and the various antitumor or anticancer agents disclosed below.
- immunoconjugates e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or
- Enzymatically active toxins and fragments thereof that can be used include, for example, diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricotheeenes. Any appropriate radionucleotide or radioactive agent known in the art or are otherwise available can be used to produce radioconjugated antibodies.
- Conjugates of the antibody and cytotoxic agent can be made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2- pyridyldithiol)propionate (SPDP); iminothiolane (IT); bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL); active esters (such as disuccinimidyl suberate); aldehydes (such as glutareldehyde); bis-azido compounds (such as bis(p-azidobenzoyl) hexanediamine); bis-diazonium derivatives (such as bis-(p- diazoniumbenzoyl)-ethylenediamine); diisocyanates (such as tolyene 2,6-diisocyanate); bis-active fluorine compounds (such as l,5-difluoro-2,4-dinitrobenzene); maleimidocaproyl (MC); valine-
- a ricin immunotoxin can be prepared as described in Vitetta et al., Science, 238: 1098 (1987).
- Carbon-14-labeled l-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacctic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody, see WO 94/11026.
- the antibody can be conjugated to a "receptor” (such as streptavidin) for utilization in tumor pre-targeting wherein the antibody- receptor conjugate is administered to the subject, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand” (e.g., avidin) that is conjugated to a cytotoxic agent (e.g., a radionucleotide).
- a "receptor” such as streptavidin
- a ligand e.g., avidin
- cytotoxic agent e.g., a radionucleotide
- a detectable marker is an agent detectable, for example, by spectroscopic, photochemical, biochemical, immunochemical, or chemical means.
- detectable markers include, but are not limited to, fluorescent dyes, chemiluminescent compounds, radioisotopes, electron-dense reagents, enzymes, colored particles, biotin, or dioxigenin.
- a detectable marker often generates a measurable signal, such as radioactivity, fluorescent light, color, or enzyme activity.
- Antibodies conjugated to detectable agents may be used for diagnostic or therapeutic purposes.
- detectable agents include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions.
- the detectable substance can be coupled or conjugated either directly to the antibody or indirectly, through an intermediate such as, for example, a linker known in the art, using techniques known in the art. See, e.g., U.S. Patent No. 4,741,900, describing the conjugation of metal ions to antibodies for diagnostic use.
- suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, and acetylcholinesterase;
- suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
- suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride and phycoerythrin; an example of a luminescent material includes luminol;
- examples of bioluminescent materials include luciferin, and aequorin.
- Antibodies useful in practicing the present invention can be prepared in laboratory animals or by recombinant DNA techniques using the following methods.
- Polyclonal antibodies can be raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the gene product molecule or fragment thereof in combination with an adjuvant such as Freund's adjuvant (complete or incomplete).
- an adjuvant such as Freund's adjuvant (complete or incomplete).
- immunogenic conjugates can be produced recombinantly as fusion proteins.
- Animals can be immunized against the immunogenic conjugates or derivatives (such as a fragment containing the target amino acid sequence) by combining about 1 mg or about 1 microgram of conjugate (for rabbits or mice, respectively) with about 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. Approximately 7 to 14 days later, animals are bled and the serum is assayed for antibody titer. Animals are boosted with antigen repeatedly until the titer plateaus. The animal can be boosted with the same molecule or fragment thereof as was used for the initial immunization, but conjugated to a different protein and/or through a different cross-linking agent. In addition, aggregating agents such as alum can be used in the injections to enhance the immune response.
- immunogenic conjugates or derivatives such as a fragment containing the target amino acid sequence
- the antibody administered can include a chimeric antibody.
- the antibody administered can include a humanized antibody.
- the antibody administered can include a completely humanized antibody.
- the antibodies can be humanized or partially humanized.
- Non-human antibodies can be humanized using any applicable method known in the art.
- a humanized antibody can be produced using a transgenic animal whose immune system has been partly or fully humanized. Any antibody or fragment thereof of the present invention can be partially or fully humanized.
- Chimeric antibodies can be produced using any known technique in the art. See, e.g., U.S. Patent Nos. 5,169,939; 5,750,078; 6,020,153; 6,420,113; 6,423,511; 6,632,927; and 6,800,738.
- the antibody administered can include a monoclonal antibody, that is, the anti-dengue antibodies of the present invention that can be monoclonal antibodies.
- Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975).
- a hybridoma method a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent.
- the lymphocytes can be immunized in vitro.
- Monoclonal antibodies can be screened as are described, for example, in Harlow & Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1988); Goding, Monoclonal Antibodies, Principles and Practice (2d ed.) Academic Press, New York (1986). Monoclonal antibodies can be tested for specific immunoreactivity with a translated product and lack of immunoreactivity to the corresponding prototypical gene product.
- Monoclonal antibodies can be prepared by recovering spleen cells from immunized animals and immortalizing the cells in conventional fashion, e.g., by fusion with myeloma cells. The clones are then screened for those expressing the desired antibody. The monoclonal antibody preferably does not cross-react with other gene products. After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.
- the monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
- the monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567.
- DNA encoding the monoclonal antibodies of the present invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).
- the hybridoma cells of the present invention can serve as a preferred source of such DNA.
- the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
- host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
- the DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide.
- non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the present invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.
- Preparation of antibodies using recombinant DNA methods such as the phagemid display method, can be accomplished using commercially available kits, as for example, the Recombinant Phagemid Antibody System available from Pharmacia (Uppsala, Sweden), or the SurfZAP TM phage display system (Stratagene Inc., La Jolla, Califorinia).
- hybridoma cell lines, transformed B cell lines, and host cells that produce the monoclonal antibodies of the present invention; the progeny or derivatives of these hybridomas, transformed B cell lines, and host cells; and equivalent or similar hybridomas, transformed B cell lines, and host cells.
- the antibodies can be diabodies.
- the term "diabodies' refers to small antibody fragments with two antigen-binding sites, which fragments include a heavy-chain variable domain (VH) connected to a light-chain variable domain (VL) in the same polypeptide chain (Vn-VL).
- VH heavy-chain variable domain
- VL light-chain variable domain
- Vn-VL polypeptide chain
- the antibody administered can include a single-chain antibody.
- the antibodies can be monovalent antibodies.
- Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain.
- the heavy chain can be truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.
- In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.
- the antibodies can be bispecific. Bispecific antibodies that specifically bind to one protein and that specifically bind to other antigens relevant to pathology and/or treatment are produced, isolated, and tested using standard procedures that have been described in the literature. [See, e.g., Pluckthun & Pack, Immunotechnology, 3:83-105 (1997); Carter, et al., J. Hematotherapy, 4:463-470 (1995); Renner & Pfreundschuh, Immunological Reviews, 1995, No. 145, pp. 179-209; Pfreundschuh U.S. Patent No. 5,643,759; Segal, et al., J.
- the antibodies disclosed herein can be formulated as immunoliposomes.
- Liposomes containing the antibody are prepared by methods known in the art. such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77: 4030 (1980); and U.S. Patent Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.
- Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition containing phosphatidylcholine, cholesterol, and PEG- derivatized phosphatidylethanolamine (PEG-PE). Liposomes can be extruded through filters of defined pore size to yield liposomes with the desired diameter.
- Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem., 257:286-288 (1982) via a disulfide-interchange reaction.
- a chemotherapeutic agent such as Doxorubicin is optionally contained within the liposome. See Gabizon et al, J. National Cancer Inst., 81(19): 1484 (1989).
- Two or more dengue antagonists can act synergistically to treat or reduce a dengue infection or a symptom of the same, for example, fever.
- a dengue antagonist can be one or more anti-dengue antibody alone or in combination with one or more other dengue antagonist, for example, a small drug pharmaceutical, or other anti-dengue therapy.
- Two or more anti-dengue antibodies, or at least one anti-dengue antibody and one or more additional therapies can act synergistically to treat or reduce the susceptibility to the at least one inflammatory condition.
- Two or more therapies, including one or more anti-dengue antibody can be administered in synergistic amounts.
- the administration of two or more therapies can have a synergistic effect on the decrease in one or more symptoms of a dengue infection, whether administered simultaneously, sequentially, or in any combination.
- a first therapy can increase the efficacy of a second therapy greater than if second therapy was employed alone, or a second therapy increases the efficacy of a first therapy, or both.
- the effect of administering two or more therapies can be such that the effect on decreasing one or more symptoms of a dengue infection is greater than the additive effect of each being administered alone.
- one therapy can enhance the efficacy of one or more other therapy on the decrease in one or more symptoms of a dengue infection, even if the amount of one or more therapy alone would have no substantial effect on one or more symptom of a dengue infection.
- Measurements and calculations of synergism can be performed as described in Teicher, "Assays for In Vitro and In Vivo Synergy," in Methods in Molecular Medicine, vol. 85: Novel Anticancer Drug Protocols, pp. 297-321 (2003) and/or by calculating the combination index (CI) using CalcuSyn software.
- Exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. [See, e.g., Fingl et. al., in The Pharmacological Basis of Therapeutics, 1975, Ch. 1 p. I.]
- the attending physician can determine when to terminate, interrupt, or adjust administration due to toxicity, or to organ dysfunctions. Conversely, the attending physician can also adjust treatment to higher levels if the clinical response were not adequate, precluding toxicity.
- the magnitude of an administrated dose in the management of disorder of interest will vary with the severity of the disorder to be treated and the route of administration. The severity of the disorder can, for example, be evaluated, in part, by standard prognostic evaluation methods.
- the dose and dose frequency can vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above can be used in veterinary medicine.
- compositions relevant to the present invention can be administered parenterally, such as by intravenous injection.
- the compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration.
- Such carriers enable the compounds relevant to the present invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, tablets, dragees, solutions, suspensions and the like, for oral ingestion by a patient to be treated.
- the therapeutic agent can be prepared in a depot form to allow for release into the body to which it is administered is controlled with respect to time and location within the body (see, for example, U.S. Patent No. 4,450,150).
- Depot forms of therapeutic agents can be, for example, an implantable composition containing the therapeutic agent and a porous or non-porous material, such as a polymer, wherein the therapeutic agent is encapsulated by or diffused throughout the material and/or degradation of the non-porous material.
- the depot is then implanted into the desired location within the body and the therapeutic agent is released from the implant at a predetermined rate.
- the therapeutic agent that is used in the present invention can be formed as a composition, such as a pharmaceutical composition containing a carrier and a therapeutic compound.
- Pharmaceutical compositions containing the therapeutic agent can include more than one therapeutic agent.
- the pharmaceutical composition can alternatively contain a therapeutic agent in combination with other pharmaceutically active agents or drugs.
- the carrier can be any suitable carrier.
- the carrier can be a pharmaceutically acceptable carrier.
- the carrier can be any of those conventionally used with consideration of chemico-physical considerations, such as solubility and lack of reactivity with the active compound(s), and by the route of administration.
- the therapeutic compounds of the present inventive methods can be formulated as inclusion complexes, such as cyclodextrin inclusion complexes, or liposomes.
- the pharmaceutically acceptable carriers described herein for example, vehicles, adjuvants, excipients, and diluents; are well-known to those skilled in the art and are readily available to the public.
- the pharmaceutically acceptable carrier can be chemically inert to the active agent(s) and one which has no detrimental side effects or toxicity under the conditions of use.
- the choice of carrier can be determined in part by the particular therapeutic agent, as well as by the particular method used to administer the therapeutic compound.
- suitable formulations of the pharmaceutical composition of the present invention There are a variety of suitable formulations of the pharmaceutical composition of the present invention.
- formulations for oral, aerosol, parenteral, subcutaneous, transdermal, transmucosal, intestinal, intramedullary injections, direct intraventricular, intravenous, intranasal, intraocular, intramuscular, intraarterial, intrathecal, intraperitoneal, rectal, and vaginal administration are exemplary and are in no way limiting. More than one route can be used to administer the therapeutic agent, and in some instances, a particular route can provide a more immediate and more effective response than another route. Depending on the specific disorder being treated, such agents can be formulated and administered systemically or locally. Techniques for formulation and administration may be found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Easton, Pa. (1990).
- Formulations suitable for oral administration can include (a) liquid solutions, such as an effective amount of the inhibitor dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions.
- Liquid formulations can include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant.
- Capsule forms can be of the ordinary hard or soft shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and corn starch.
- Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and other pharmacologically compatible excipients.
- Lozenge forms can contain the inhibitor in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles containing the inhibitor in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to, such excipients as are known in the art.
- an inert base such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to, such excipients as are known in the art.
- compositions that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers can be added.
- the therapeutic agent can be made into aerosol formulations to be administered via inhalation.
- aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also can be formulated as pharmaceuticals for non-pressurized preparations, such as in a nebulizer or an atomizer. Such spray formulations also may be used to spray mucosa.
- Topical formulations are well known to those of skill in the art. Such formulations are particularly suitable in the context of the invention for application to the skin.
- Injectable formulations are in accordance with the present invention.
- the parameters for effective pharmaceutical carriers for injectable compositions are well-known to those of ordinary skill in the art [see, e.g., Pharmaceutics and Pharmacy Practice, J. B. Lippincott Company, Philadelphia, PA, Banker and Chalmers, eds., pages 238250 (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., pages 622 630 (1986)].
- the agents of the present invention can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
- penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
- Formulations suitable for parenteral administration can include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
- the therapeutic agent can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol or hexadecyl alcohol, a glycol, such as propylene glycol or polyethylene glycol, poly(ethyleneglycol) 400, glycerol, dimethylsulfoxide, ketals such as 2,2-dimethyl-l,3- dioxolane-4-methanol, ethers, oils, fatty acids, fatty acid esters or glycerides, or acetylated fatty acid glycerides with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.
- Oils which can be used in parenteral formulations, include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
- Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts
- suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-beta-aminopropionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (e) mixtures thereof.
- the parenteral formulations can contain from about 0.5% to about 25% by weight of the drug in solution. Preservatives and buffers can be used. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants having a hydrophilic-lipophilic balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations will typically range from about 5% to about 15% by weight. Suitable surfactants include polyethylene glycol sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
- HLB hydrophilic-lipophilic balance
- parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use.
- sterile liquid excipient for example, water
- Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.
- the therapeutic agent can be made into suppositories by mixing with a variety of bases, such as emulsifying bases or water-soluble bases.
- bases such as emulsifying bases or water-soluble bases.
- Formulations suitable for vaginal administration can be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulas containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.
- Agents intended to be administered intracellularly may be administered using techniques well known to those of ordinary skill in the art.
- such agents can be encapsulated into liposomes.
- Liposomes are spherical lipid bilayers with aqueous interiors. Molecules present in an aqueous solution at the time of liposome formation are incorporated into the aqueous interior.
- the liposomal contents are both protected from the external microenvironment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm. Additionally, due to their hydrophobicity, small organic molecules may be directly administered intra-cellularly.
- Materials and methods described for one aspect of the present invention can also be employed in other aspects of the present invention. For example, a material such a nucleic acid or antibody described for use in screening assays can also be employed as therapeutic agents and vice versa.
- Anti-dengue antibodies of the present invention can be administered to a subject before, during, and/or after diagnosing the patient as having a dengue infection.
- Dengue infection is caused by any one of four distinct but closely related dengue virus (DENV) serotypes (called DENV-1, -2, -3, and -4).
- DENV-1, -2, -3, and -4 distinct but closely related dengue virus serotypes
- These dengue viruses are single-stranded RNA viruses that belong to the family Flaviviridae and the genus Flavivirus-a family which includes other medically significant vector-borne viruses (for example, West Nile virus, Yellow Fever virus, Japanese Encephalitis virus, St. Louis Encephalitis virus, and the like).
- Dengue viruses are arboviruses (arthropod-borne virus) that are transmitted primarily to humans through the bite of an infected Aedes species mosquito. Transmission may also occur through transfusion of infected blood or transplantation of infected organs or tissues. Human transmission of dengue is also known to occur after occupational exposure in healthcare settings (for example, needle stick injuries) and cases of vertical transmission have been described in the literature (that is, transmission from a dengue infected pregnant mother to her fetus in utero or to her infant during labor and delivery).
- dengue serotypes can produce the full spectrum of illness and severity.
- the spectrum of illness can range from a mild, non-specific febrile syndrome to classic dengue fever (DF), to the severe forms of the disease, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Severe forms typically manifest after a two to seven day febrile phase and are often heralded by clinical and laboratory warning signs.
- Management of dengue can include timely and judicious use of supportive care, including administration of isotonic intravenous fluids or colloids, and close monitoring of vital signs and hemodynamic status, fluid balance, and hematologic parameters.
- DHF can usually be distinguished from DF as it progresses through its three predictable pathophysiological phases.
- a febrile phase can include viremia-driven high fevers.
- a critical/plasma leak phase can include sudden onset of varying degrees of plasma leak into the pleural and abdominal cavities.
- a convalescence or reabsorption phase can include a sudden arrest of plasma leak with concomitant reabsorption of extravasated plasma and fluids.
- the anti-dengue antibodies of the present invention can be administered during any phase or combination of phases.
- Dengue infected patients are either asymptomatic or they can have one of three clinical presentations: undifferentiated fever, dengue fever with or without hemorrhage, or dengue hemorrhagic fever or dengue shock syndrome. As many as one half of all dengue infected individuals are asymptomatic, that is, they have no clinical signs or symptoms of disease.
- the first clinical course is a relatively benign scenario where the patient experiences fever with mild non-specific symptoms that can mimic any number of other acute febrile illnesses. They may not meet case definition criteria for DF.
- Dengue fever with or without hemorrhage patients are typically older children or adults and they can present within two to seven days of high fever (occasionally biphasic) and have two or more of the following symptoms: severe headache, retro-orbital eye pain, myalgias, arthralgias, a diffuse erythematous maculo-papular rash, and mild hemorrhagic manifestation.
- Other forms of hemorrhage such as epistaxis, gingival bleeding, gastrointestinal bleeding, or urogenital bleeding can also occur, but are rare.
- Leukopenia is frequently found and may be accompanied by varying degrees of thrombocytopenia. Children may also have nausea and vomiting. Patients with DF do not generally develop substantial plasma leak (as in DHF and DSS) or extensive clinical hemorrhage.
- Serological testing for anti-dengue IgM antibodies or molecular testing for dengue viral RNA or viral isolation can confirm the diagnosis.
- Clinical presentation of DF and the early phase of DHF are similar. With close monitoring of key indicators, the development of DHF can be detected at the time of defervescence so that early and appropriate therapy can be initiated.
- DHF Dengue hemorrhagic fever
- DSS dengue shock syndrome
- Dengue viremia is typically highest in the first three to four days after onset of fever but then falls quickly to undetectable levels over the next few days. The level of viremia and fever usually follow each other closely, and anti-dengue IgM anti-bodies increase as fever abates.
- Patients with plasma leak can be monitored for early changes in hemodynamic parameters consistent with compensated shock such as increased heart rate (tachycardia) for age especially in the absence of fever, weak and thready pulse, cool extremities, narrowing pulse pressure (systolic blood pressure minus diastolic blood pressure ⁇ 20 mmHg), delayed capillary refill (>2 seconds), and decrease in urination (i.e., oliguria).
- compensated shock such as increased heart rate (tachycardia) for age especially in the absence of fever, weak and thready pulse, cool extremities, narrowing pulse pressure (systolic blood pressure minus diastolic blood pressure ⁇ 20 mmHg), delayed capillary refill (>2 seconds), and decrease in urination (i.e., oliguria).
- Patients exhibiting signs of increasing intravascular depletion, impending or frank shock, or severe hemorrhage can be admitted to an appropriate level intensive care unit for monitoring and intravascular volume replacement.
- Anticipatory management and monitoring indicators can be used in effectively administering therapies as the patient enters the critical phase.
- New-onset leucopenia WBC ⁇ 5,000 cells/mm3 with a lymphocytosis and an increase in atypical lymphocytes indicate that the fever will likely dissipate within the next 24 hours and that the patient is entering into the critical phase.
- Indicators that suggest the patient has already entered the critical phase include sudden change from high (>38.0 centigrade) to normal or subnormal temperatures, thrombocytopenia (100,000 or less cells/mm 3 ) with a rising or elevated hematocrit (20% or more increase from baseline), new hypoalbuminemia or hypocholesterolemia, new pleural effusion or ascites, and signs and symptoms of impending or frank shock.
- the critical period can last less than 24 to 48 hours. Most of the complications that arise during this period-such as hemorrhage and metabolic abnormalities (for example, hypocalcemia, hypoglycemia, hyperglycemia, lactic acidosis, and hyponatremia) are frequently related to prolonged shock.
- the principal objective during this period can be to prevent prolonged shock and support vital systems until plasma leak subsides. Careful attention can be paid to the type of intravenous fluid (or blood product if transfusion is needed) administered, the rate, and the volume received over time. Frequent monitoring of intravascular volume, vital organ function, and the patient's response can be performed. Monitoring for overt and occult hemorrhage can be performed. Transfusion of volume-replacing blood products can be implemented if substantial hemorrhage is suspected during this phase.
- the convalescent (reabsorption) phase can begin when the critical phase ends and is characterized when plasma leak stops and reabsorption begins. During this phase, fluids that leaked from the intravascular space (i.e., plasma and administered intravenous fluids) during the critical phase are reabsorbed. Indicators suggesting that the patient is entering the convalescent phase include sense of improved well-being reported by the patient, return of appetite, stabilizing vital signs (widen pulse pressure, strong palpable pulse), bradycardia, hematocrit levels returning to normal, increased urine output, and appearance of the characteristic convalescence rash of dengue (i.e., a confluent sometimes pruritic, petechial rash with multiple small round islands of unaffected skin).
- an acute-phase serum specimen can be collected for serology at least 7 days before onset of fever and paired with convalescent serum drawn at least 7 days after the acute phase, optimally 14-21 days after onset of fever (Halstead, Annu. Rev. Entomol., 53:273-291 (2008); Kurosu et al., Biochem. Biophys. Res. Commun. 394:398-404 (2010)).
- SPYMEG (Kubota-Koketsu et al., Biochem. Biophys. Res. Commun., 387:180-185 (2009)) was used as fusion partner cells, to develop hybridomas producing specific HuMAbs.
- SPYMEG cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 15% fetal bovine serum (FBS) in a 5% CO 2 incubator at 37 centigrade.
- Vero cells were maintained in minimum essential medium (MEM) with 10% FBS in a 5% CO 2 incubator at 37 centigrade.
- Mosquito-derived cell line C6/36 was maintained in Leibovitz's L-15 medium with 10% FBS and 0.3% tryptose phosphate broth in an incubator at 28 centigrade.
- the DENVs used in this study were Mochizuki strain DENV-1, 16681 and New Guinea C (NGC) strains DENV-2, H87 strain DENV-3, and H241 strain DENV-4.
- the culture supernatants from C6/36 cells infected with individual strains were used as viral stocks.
- Virus titer was estimated as focus-forming unit (FFU), as described previously (Kurosu et al., Biochem. Biophys. Res. Commun. 394:398-404 (2010)).
- D2L (5'- ATCCAGATGTCATCAGGAAAC-3') SEQ ID NO: 203/ D2R (5'- CCGGCTCTACTCCTATGATG-3') SEQ. ID NO. 204, D3L (5'-CAATGTGCTTGAATACCTTTGT-3') SEQ ID NO: 205/ D3R (5'-GGACAGGCTCCTCCTTCTTG-3') SEQ. ID NO. 206, and D4L (5'-GGACAACAGTGGTGAAAGTCA-3') SEQ ID NO: 207/ D4R (5'-GGTTACACTGTTGGTATTCTCA-3') SEQ. ID NO. 208, which are specific to individual serotypes of DENV, DENV-1, -2, -3, and -4, respectively.
- Hybridomas were prepared as follows. About 10 milliliters of blood were obtained from individual patients and the PBMCs were prepared by centrifugation through Ficoll-PaqueTM PLUS (GE Healthcare, Uppsala, Sweden) for 40 min at 1,700 rpm (520 g). The PBMCs were fused with SPYMEG cells at a ratio of 10:1 with polyethylene glycol 1500 (Roche Diagnostics Japan, Tokyo, Japan). Fused cells were cultured in DMEM supplemented with 15% FBS and 3% BM-condimed (Roche Diagnostics Japan, Tokyo, Japan) in a 96-well microplate for 10-14 days in the presence of hypoxanthine-aminopterin-thymidine (HAT).
- HAT hypoxanthine-aminopterin-thymidine
- the first screening of the culture media for antibody specificity against DENV was performed by indirect immunofluorescence (IF) assay. Wells producing specific antibody were next subjected to cell cloning by limiting dilution. After 10-14 days, the second screening was also performed by IF assay.
- IF indirect immunofluorescence
- HuMAbs were purified from hybridoma in a large-scaled culture of 1 liter using serum-free medium (Hybridoma SFM, Life Technologies). Antibody IgG in the culture fluids was purified by column chromatography of protein G (HiTrap Protein G HP Columns, GE health care), according to the manual recommended by the company. After purification, the purified HuMAbs was dialyzed by Slide-A-Lyzer Dialysis Cassettes, 10K MWCO, 0.5 - 3 ml Capacity (Thermo scientific) and filtrated by syringe filter (0.2 m pore size). The concentration of IgG was measured by BCA method using Pierce (R) BCA TM Protein Assay Kit (Thermo scientific).
- the IF assay was prepared as follows. Vero cells, at 2.5 x 10 4 per well in a 96-well microplate, were mock-infected or infected with DENV. After incubation for 16-24 hr, the cells were fixed with 3.7% formaldehyde in phosphate-buffered saline (PBS) and permeabilized with 1% Triton X-100 in PBS. Undiluted hybridoma culture fluids were used for the HuMAbs. Also, the purified HuMAb of 10.0 micrograms/ml were serially two-fold diluted and these dilutions were used. Vero cells in 96-well microplate were incubated with the hybridoma culture fluids or the serial dilutions.
- PBS phosphate-buffered saline
- the VN assay was conducted on culture media of individual hybridoma clones, as described previously (Okuno et al., Biken J 21: 137-147 (1978)).
- the 25 microlitters of undiluted hybridoma culture supernatant, or DMEM supplemented with 15% FBS (as a negative control) was mixed with 100 FFU of individual DENV serotypes (25 microlitters). After incubation for 15 min, the mixture was used to infect Vero cells in a 96-well microplate. After inoculation at 37 centigrade for 2 hr, 100 microlitters of MEM with 3% FBS was added.
- microlitters of purified HuMAb with variable concentrations of IgG (2-fold serial dilutions of 25.0 micrograms/ml) or PBS (as a negative control) was mixed with 100 FFU of individual DENV serotypes (25 microlitters). After incubation at 37 centigrade for 15 min, the mixture was used to infect Vero cells in a 96-well microplate. After inoculation at 37 centigrade for 2 hr, supernatant was removed. And 100 microlitters of MEM with 1% carboxymethylcellulose, 2% FBS was added.
- the cells were fixed with 3.7% formaldehyde in PBS and permeabilized with 1% Triton X-100 in PBS.
- the plate was stained with 4G2 at 4 centigrade overnight, as for the IF assay.
- the bound antibody was visualized by further reaction with an AlexaFluor 488-conjugated anti-mouse antibody (1:1,000; Invitrogen).
- the assays were performed in triplicate and the results expressed as averages and standard deviation.
- the neutralization activity was expressed as the concentration showing a 50% reduction in FFU compared with the negative control calculated by Behrens-Karber method (Kains CD (1991) Principles of Toxicology. In Pharmacological Basis of Therapeutics, pp. 49-61. Edited by Gilman AG, Tall TW, Nies AS, Taylor P. 8th edition. McGraw-Hill) (referred to as the VN50).
- the antibody-dependent enhancement (ADE) assay was performed as follows.
- the purified HuMAbs (serial 10-fold dilutions of 10.0 micrograms/ml) were incubated with DV1 to DV4 at 37 centigrade for 30 min.
- THP-1 cells without FBS condition were inoculated with the HuMAb-DENV mixed solution and incubated at 37 centigrade for further 1hr.
- FBS addition at a final concentration of 2%
- the THP-1 solution with HuMAb and DENV were cultured at 37 centigrade for 3 days.
- Total RNA extracted from the collected infected cells using TRIzol (R) reagent (life technologies) was applied to one-step real-time PCR.
- One-step real-time PCR was performed as described previously (Shu et al., J Clin Microbiol. 41:2408-2416 (2003)). Briefly, the oligonucleotide primer pairs were used for One-step real-time PCR: DV-F (5'-CAATATGCTGAAACGCGAGAGAAA-3') (SEQ. ID NO. 209),/DV-N (5'-CCCCATCTATTCAGAATCCCTGCT-3') (SEQ. ID NO. 210),were designed to give amplicons from all serotyped of DENV and GAPDH-F (5'-ACCACAGTCCATGCCATCAC-3') (SEQ. ID NO.
- the following expression vectors were used for DENV proteins.
- the CMV4-HA vector was used for the molecular cloning of a fusion form of the E and prM (prM-E) and E protein of DENV genes.
- prM-NotI Fw GGAGCGGCCGCGTTCCATTTAACCACACGTAACGG
- Env-EcoRV Rv GGCGATATCGGCCTGCACCATGACTCCCAAATAC (SEQ. ID NO. 218)) according to the manufacturer's instructions.
- the amplified DNA fragments were digested with NotI and EcoRV and ligated with the NotI- and EcoRV-digested CMV4-HA Expression Vector.
- the pcDNA3-C-Flag vector was used for the molecular cloning of the prM and C DENV genes.
- the mammalian expression plasmid pcDNA3 (Invitrogen) was digested with restriction enzymes (EcoRV and XhoI), and double-stranded oligoDNA (5'- ATCGACTACAAAGACGATGACGACAAGCT(SEQ. ID NO. 219) and 5'- TCGATCAAAGCTTGTCGTCATCGTCTTTGTAGTCGATATC-3'(SEQ. ID NO. 220)) was inserted between the EcoRV and XhoI sites.
- EcoRV and XhoI restriction enzymes
- the coding regions for the prM protein from the 16681 and NGC strains of DENV-2 were amplified with PrimeSTAR GXL DNA polymerase (Takara) with gene-specific primers (DV2 prM F BglII, CGAGATCTGCCACCATGTTCCATTTAACCACACGTAAC(SEQ. ID NO. 221); and DV2 prM R SmaI, GCCCCGGGGATATCTGTCATTGAAGGAGTGACAGC(SEQ. ID NO. 222)) following the manufacturer's instructions.
- the amplified DNA fragments were digested with BglII and SmaI and ligated with the BamHI- and EcoRV-digested pcDNA3-C-Flag vector.
- the DENV-2 C gene was amplified with PrimeSTAR Max DNA polymerase (Takara) with gene-specific primers (D2 C F, GGATCTCCAGCCATGAATGACCAACGGAAAAAGGCG(SEQ. ID NO. 223); and D2 C R, GTCGATGGGGATATCTCTGCGTCTCCTATTCAAGATG(SEQ. ID NO. 224)) following the manufacturer's instructions.
- the amplified DNA fragments were cloned into plasmids with the In-Fusion Advantage PCR cloning kit (Takara).
- the NS1 gene was cloned as reported previously (Kurosu et al., Biochem Biophys Res Commun 362: 1051-1056 (2007).
- HuMAbs were isotyped as follows. The HuMAbs obtained were isotyped by Human IgG ELISA Quantitation set, Human IgM ELISA Quantitation set, and Human IgA ELISA Quantitation set (Bethyl Laboratories, Inc., Montgomery, Texas). The fluids of individual hybridoma clone cultures were used for this isotyping. Further, for subclassing of the HuMAbs, ELISA microplates Maxsorp (Nunc, Copenhagen, Denmark) were coated overnight at 4 centigrade with 50 microlitters of goat anti-human IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) in 0.05 M Sodium Bicarbonate buffer, pH 8.6 (1 microgram/ml).
- the wells were incubated with 300 microlitters of 0.5 % BSA in PBS blocking buffer for 1 hr. at 37 centigrade. After washing again, the wells were incubated with 50 microlitters of hybridoma supernatant or control serum for 2 hrs. at 37 centigrade.
- PCR products were ligated into pGEM T-Easy vector (Promega, Madison, Wisconsin), and their sequences were analyzed using a BigDye Terminator v3.1 Cycle Sequencing Kit and an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, California).
- the preparation of hybridomas producing HuMAbs against DENV using specimens from Thai patients was examined.
- the PBMC samples were obtained from patients in the acute (around one week after onset of fever) and convalescent phases (around two weeks after onset of fever).
- a total of nine samples from Thai patients were used: three patients (D30, D32, and D33) in the acute phase, ranging between 6-8 days after onset of fever; four patients (D22, D25, D27, and D28) in the convalescent phase, 12-15 days after onset of fever; and one patient in both acute (D23; 5 days after onset of fever) and convalescent phases (D26; 19 days after onset of fever) (Tables 1).
- D22, D27, and D30 were clinically diagnosed as DHF infections and the others were all DF.
- Data obtained from the rapid test kits showed that all acute-phase patients were positive for both anti-dengue IgG and IgM, indicating that these patients had secondary DENV infections.
- the acute-phase plasma samples were also subjected to RT-PCR, for DENV serotyping.
- the first PCR was performed with primers DEUL and DEUR, which are common to all DENV serotypes.
- the resulting products were then subjected to a second PCR with primers specific to individual serotypes of DENV: D1L and D1R for DENV-1; D2L and D2R for DENV-2; D3L and D3R for DENV-3; and D4L and D4R for DENV-4.
- the resulting products were detected only by D2L and D2R, but not by other primer sets, in all samples from the 4 acute-phase patients (data not shown), indicating that all 4 patients were cases of secondary infection with DENV-2.
- Hybridomas were prepared as follows. The PBMC fractions prepared from four acute-phase patients and five convalescent-phase patients were used to prepare hybridoma by fusion with SPYMEG cells. Fused cells were seeded and cultured for 10-14 days in HAT selection medium in 96-well microplates. The first screening of individual well culture fluids revealed unexpectedly high efficiencies. With the addition of DENV-infected cells, wells with acute-phase PBMCs were more frequently IF-positive (734 wells) than convalescent-phase PBMCs (57 wells).
- IgA-type was detected only in 6.6% (8/121) of HuMAbs from acute-phase cells. There were no positive cases for IgM-type. There were no positive reactions in four clones for any of IgG, IgA, and IgM under the conditions examined using the culture fluids of hybridoma clones.
- HuMAbs Cross-reactivity of HuMAbs was determined as follows. The HuMAbs obtained as described above were characterized for their serological reactivity to all four DENV serotypes by IF and VN assays. HuMAbs in the fluids of individual hybridoma cell cultures were used for these assays.
- the HuMAbs were classified into groups 1 to 10 and groups A to X based on their cross-reactivity with the four serotypes of DENV in IF and VN assays, respectively: group A showed no VN activity to any of four serotypes; groups 1-2 and groups B-E showed specific reactions with a single serotype; groups 3-6 and groups F-H showed cross-reactions with two serotypes; groups 7-9 and groups I-O showed cross-reactions with three serotypes; and group 10 and groups P-X showed cross-reactions with all four serotypes.
- the IF assay revealed that 109 of 121 clones (90.1%) derived from acute-phase patients were cross-reactive with all four serotypes (Figure 1): 65 of 75 clones (86.7%) from D23, 23 of 25 clones (92.0%) from D30, five of five clones (100%) from D32, and 16 of 16 clones (100%) from D33 ( Figure 2 and Table 2).
- the IF profiles of several representative HuMAbs by IF are shown in Figure 3: D28-2B11D10 and D23-4A7D6 were serotype-specific, D28-2B11F9 and D23-1B11A5 were cross-reactive with two serotypes, D25-4D3D2 and D23-3E6D7 were cross-reactive with three serotypes, and D22-1B7G2 were cross-reactive with all four serotypes.
- Mouse MAb 4G2 was used as a positive control for antibodies reactive with all four serotypes (corresponding to group 10).
- VN activity of HuMAbs The culture fluids from individual hybridoma clones were reacted with DENV-1 to -4. Under these conditions, the control 4G2 showed a 90% reduction in FFU compared with the negative control (DMEM with 15% FBS) in all four serotypes of DENV and, therefore, this MAb was classified into group X.
- the correlations between IF and VN results ( 50% and 90% reduction) for individual HuMAbs are shown in Figure 4.
- the obtained HuMAbs were highly heterogeneous.
- HuMAbs with neutralization activities to all four serotypes of DENV were more efficiently obtained using acute-phase PBMCs.
- Tables 2-4 shows summarized results of viral protein recognized by HuMAbs.
- 293T cells transfected with expression vectors for the DENV-2 prM, E, NS1, and C proteins, or for the prM-E fusion protein, were used as targets for the identification of viral proteins recognized by individual HuMAbs by IF.
- Summarized data on viral proteins recognized by individual HuMAbs classified in groups 1 to 10 by IF assay and in groups A to X by VN assay are shown in Tables 3 and 4, respectively (the results from individual HuMAbs are shown in Table 2).
- 99 were reactive with E, eight with prM, four with NS1, and none with C.
- the 98 HuMAbs recognizing E (96 of 99 HuMAbs from the acute-phase and two of two HuMAbs from the convalescent-phase) were all in group 10 (cross-reactive with all four serotypes) according to the IF assay (Table 3). Of these, 70 acute-phase and one convalescent-phase HuMAbs showed 50% VN activity against all four DENV serotypes (groups P to X). Of the 70 acute-phase HuMAbs, 11 also showed 90% VN activity against all four DENV serotypes (group X).
- Tables 2-4 show a summary of the cross-reactivity of HuMAbs with Japanese Encephalitis Virus (JEV).
- JEV Japanese Encephalitis Virus
- HuMAbs from acute phase were reactive with JEV and belonged to groups other than group 10: two in group 8 recognized DENV E and one in group 7 recognized NS1.
- the HuMAbs were examined for VN activity against JEV.
- a total of 55 HuMAb clones showed 50% VN activity against JEV, although none showed 90% VN activity.
- 50 (46 recognizing E, two recognizing NS1, and two recognizing "Other") of the above 55 HuMAbs were from acute phase and remained five HuMAbs recognizing NS1 were from convalescent phase (Table 2 shows the data for individual HuMAbs).
- VN activity against JEV was observed not only for HuMAbs cross-reactive with all four DENV serotypes (38 in groups P to X from the acute phase), but also for HuMAbs cross-reactive with two or three DENV serotypes (six from the acute phase and one from the convalescent phase in groups F to O), for DENV serotype-specific HuMAbs (three from the acute phase in groups B to E), and for HuMAbs with no VN activity to any of the DENV serotypes (three from the acute phase and four from the convalescent phase in group A). Selection of 18 hybridoma clones producing stronger neutralizing antibodies to all four serotypes of DENV.
- a total of 18 hybridoma clones producing specific HuMAbs against DENV were selected as producers of antibody with higher neutralizing titers from a total of 136 hybridoma clones, 121 obtained from 4 Thai patients in the acute phase and 15 from 5 Thai patients in the convalescent phase, according to the results by viral neutralizing activity assay using the culture fluids of individual hybridomas against the laboratory strains of DENV-1 to DENV-4 serotypes (Setthapramote et al., Biochem Biophy Res Commun 423: 867-872 (2012)). All these 18 clones selected as the producers of HuMAbs showing >85% inhibition of viral replication in all four serotypes were derived from three patients in the acute phase (Table 5).
- Table 6s show a summary of sequences of the HuMAbs.
- the variable regions of IgG in individual above 18 HuMAbs, CDR1, CDR2, and CDR3 were cloned and sequenced.
- FIG.7 show a summary of VN and ADE activities of 18 HuMAbs to four serotypes of DENV.
- Enough amounts of HuMAbs were purified by protein G column chromatography from the culture fluids from individual hybridoma clones that were adapted to serum-free medium and cultured in a large scale.
- Serial dilutions of the purified HuMAbs from individual hybridoma clones were reacted with DENV-1 to DENV-4.
- the serial 2-fold dilutions of 25.0 micrograms/ml were used for reaction with viral proteins in infected Vero cells by indirect IF assay.
- the lowest dilutions of the HuMAbs to individual DENV serotypes were used for the binding activities to viral protein.
- stronger binding activities to DENV were observed in all the 18 HuMAbs than 4G2, especially to DENV-1 and DENV-2.
- Figure 7 shows the activities of individual HuMAbs in the concentrations ranging from 25.0 to 0.20 micrograms/ml by serial 2-fold dilution of 25.0 micrograms/ml for VN assay to DENV-2 in Vero cells and in the concentrations ranging from 10.0 to 0.0001 micrograms/ml by serial 10-fold dilution of 10.0 micrograms/ml for ADE assay to DENV-2 in THP-1 cells.
- 4G2 murine MAb as a positive control and 5E4 human anti-influenza MAb as a negative control were used. The results for VN and ADE were shown in individual HuMAbs.
- FIG. 1 illustrates summary of HuMAbs and their cross-reactivity to DENV-1 to -4 in IF and VN assays.
- a total of 121 acute-phase HuMAbs and 15 convalescent-phase HuMAbs were examined for cross-reactivity and cross-neutralization against DENV serotypes in IF and VN assays, respectively.
- Culture fluids of HuMAb-producing hybridoma clones were used.
- the HuMAbs were classified as groups 1 to 10 and groups A to X according to their cross-reactivity against the four serotypes of DENV in IF assay and VN assay, respectively. Individual groups are shown by different colors.
- Vero cells individually infected with DENV-1 to -4 were used as target cells in these assays.
- the data from VN assay are shown by the degree of neutralization ("-", ⁇ 50%; "+”, 50% to ⁇ 90%; and "++", 90% neutralization).
- FIG. 2 illustrates representation of the percentages of HuMAbs obtained from individual patients for their cross-reactivity with DENV-1 to -4 by IF and VN assays.
- a total of 121 acute-phase HuMAbs 75 from D23, 25 from D30, five from D32, and 16 from D33
- 15 convalescent-phase HuMAbs four from D22, five from D25, two from D26, two from D27, and two from D28) were examined for their cross-reactivity and cross-neutralization against four serotypes of DENV.
- Culture fluids from the HuMAb-producing individual hybridoma clones were used for these assays.
- the HuMAbs were classified into groups 1 to 10 and groups A to X according to their cross-reactivity with the four serotypes of DENV as assessed by IF assay and VN assay, respectively. Individual groups are shown by different colors. Vero cells individually infected with DENV-1 to -4 were used as target cells in these assays. The data from VN assays are shown by the degree of neutralization ("+”, 50% to ⁇ 90%; and "++", 90% neutralization).
- FIG. 3 shows staining profiles of HuMAbs by IF assay.
- Vero cells mock-infected with PBS or individually infected with DENV-1 to -4 were used as target cells.
- 4G2 anti-flavivirus E mouse MAb was used as a positive control.
- FIG. 4 shows a correlation between IF and VN results.
- a total of 121 acute-phase HuMAbs and 15 convalescent-phase HuMAbs are shown separately to highlight the correlation between IF and VN ("-", ⁇ 50%; “+”, 50% to ⁇ 90%; and “++”, 90% neutralization) according to their cross-reactivity with different DENV serotypes (groups 1 to 10 according to the IF assay and groups A to X according to the VN assay).
- Culture fluids of HuMAb-producing hybridoma clones were used. Individual groups are shown by different colors, as in Figure 1. Vero cells individually infected with DENV-1 to -4 were used as target cells in these assays.
- FIG. 5 shows binding limits of 18 HuMAbs to four serotypes of DENV by indirect IF assay.
- Vero cells in 96-well microplate were infected with DENV. After incubation for 2 days, the cells were fixed with formaldehyde, then reacted with the serial 10-fold dilutions of the purified individual HuMAbs (10.0 micrograms/ml).
- the final antibody concentration showing positive reaction is shown in figure.
- FIG. 6 shows VN activity of 18 HuMAbs to four serotypes of DENV.
- Vero cells in 96-well microplate were infected with individual serotypes of DENV which had been incubated with serial 2-fold dilutions of the purified HuMAbs (25.0 micrograms/ml) at 37 centigrade for 30 min, and incubated at 37 centigrade for overnight. Finally, the cells were fixed and infected cells were detected by IF assay with 4G2.
- FIGs. 7 show VN and ADE activities of 18 HuMAbs to DENV-2.
- Vero cells were infected with DENV2 (16681 strain) which had been incubated with serial 2-fold dilutions of the purified HuMAbs (25.0 micrograms/ml) at 37 centigrade for 30 min, and incubated at 37 centigrade for overnight. Finally, the cells were fixed and infected cells were detected by IF assay with 4G2.
- THP-1 cells were infected with DENV-2 (16681 strain) which had been incubated with serial 10-fold dilutions of the purified HuMAbs (10.0 micrograms/ml) at 37 centigrade for 30 min, then incubated for 3 days.
- FIG. 7-1 shows 4G2, 5E4, D23-1A10H7 and D23-1B3B9.
- FIG. 7-2 shows D23-1C2D2, D23-1G7C2, D23-1H5A11 and D23-3A10G2.
- FIG. 7-3 shows D23-4A6F9, D23-4F5E1, D23-4H12C8 and D23-5E6B1.
- FIG. 7-4 shows D23-5G2D2, D23-5G8E3, D23-1C1G4 and D30-1E7B8.
- FIG. 7-5 shows D30-3A1E2, D30-33B6C7, D32-2D1G5 and D32-2H8G1.
- FIG.8 shows ADE activities of representative two HuMAbs to four serotypes of DENV.
- ADE assays four serotypes of DENV (Mochizuki strain of DENV-1; 16681 strain of DENV-2; H87 strain of DENV-3; and H241 strain of DENV-4) were used as in Fig. 7. The infection was performed at an MOI of 0.05.
- FIG.9 shows IF binding activity of representative HuMAbs to clinical isolates of DENV.
- Representative HuMAbs, D23-1A10H7, D23-1B3B9, and D23-1G7C2 were examined for the detection limit by IF assay to clinical isolates DV1-1 to DV1-5, DV2-1 to DV2-5, DV3-1 to DV3-5, and DV4-1 to DV4-5.
- FIG.10 shows VN activity of representative HuMAbs to clinical isolates of DENV.
- Representative HuMAbs, D23-1A10H7, D23-1B3B9, and D23-1G7C2 were examined for VN50 assay to clinical isolates DV1-1 to DV1-5, DV2-1 to DV2-5, DV3-1 to DV3-5, and DV4-1 to DV4-5.
- FIG.11 shows the results of in vivo therapeutic efficiency of HuMAbs in suckling mice.
- FIG.12 shows examples of the pictures of Immunofluorescent assay of positive control, negative control, Hybridoma clones DMSc-17, DMSc-14 and DMSc-36.
- FIG.13 shows illustration of 22 clones showing VN reduction to DENV1, DENV2, DENV3, DENV4 higher than 80%. All clones showed VN to DENV1 and DENV2 higher than 90%. The 10 clones showed VN to DENV3 and 16 clones showed VN to DENV4 higher than 90%.
- the HuMAbs to neutralize DENV-1 to DENV-4 by in vitro assay as above were next examined for their in vivo therapeutic efficacy by animal model using suckling mice.
- PBS in place of the solution containing HuMAb was used as a negative control.
- one in 10 mouse treated with HuMAbs were died, although all mice treated with PBS were died around 13 to 15 days after virus inoculation (Figure 11).
- a total of 136 hybridoma clones producing specific HuMAbs against DENV were obtained using PBMCs from nine blood samples from eight patients.
- the four acute-phase patients were all secondarily infected with DENV-2.
- These samples efficiently generated hybridomas producing specific and robust HuMAbs [121 clones: 99 recognizing E, eight recognizing prM, four recognizing NS1, none recognizing C, and 10 recognizing other unknown viral protein(s)], compared with those from the five convalescent-phase patients (15 clones: two recognizing E, two recognizing prM, eight recognizing NS1, none recognizing C, and three recognizing other unknown proteins).
- VN assays also revealed that a greater proportion of HuMAbs prepared from acute-phase PBMCs were able to neutralize all four serotypes of DENV [57.9% (70/121) acute-phase clones, versus 6.7% (1/15) convalescent-phase clones].
- Antibodies at the acute phase showed complex cross-reactivity with all four DENV serotypes, with much stronger VN activity not only against DENV-2, which was replicating in the patient, but also against the other serotypes of DENV and against JEV.
- HuMAbs There are several options for methods to prepare HuMAbs: humanization of murine MAbs, the creation of chimeras of human and murine MAbs, HuMAb preparation by phage display, immortalization of antibody-producing cells by EBV, and cell-to-cell fusion of human antibody-producing cells with myeloma cells (Marasco et al., Nat Biotech 25: 1421-1434 (2007)).
- PBMC samples in this study were collected from patients at the acute phase (5-8 days after the onset of fever) or at the convalescent phase (12-19 days for convalescent phase) of secondary infection. This study enabled us to compare the efficiency of obtaining HuMAbs at each stage. From the acute-phase PBMCs, 81.8% anti-E, 6.6% anti-prM, and 3.3% anti-NS1 HuMAbs were obtained, while 13.3% anti-E, 13.3% anti-prM, and 53.3% anti-NS1 HuMAbs were obtained from convalescent-phase PBMCs.
- Several groups have used PBMCs from convalescent-phase, but not acute-phase, patients to prepare HuMAbs by immortalizing patient-derived B cells with EBV.
- Dejnirattisai et al. (Dejnirattisai et al., Science 328: 745-748 (2010)) prepared anti-E and anti-prM HuMAbs using B cells from seven DENV-infected patients 15-24 days after defervescence. They observed that 89% of anti-E HuMAbs were cross-reactive with all four serotypes. Surprisingly, their studies resulted in the preparation of more anti-prM than anti-E HuMAbs. The anti-prM HuMAbs were also highly cross-reactive with all four serotypes of DENV (94%) and potently promoted ADE.
- domain III of the E protein is the main target of anti-flavivirus neutralizing antibodies in mice (Oliphant et al., J Virol 81: 11828-11839 (2007)), they also performed a large screen to gain insights into the domain specificity and cross-reactivity of E domain III-specific antibodies isolated from two patients, one with a primary infection (donor 13) and the other with a secondary infection (donor 12). From donor 13, 18 of 152 HuMAbs were reactive with domain III (13 type-specific, one cross-reactive with three serotypes, and four cross-reactive with all four serotypes).
- HuMAbs differentiated their HuMAbs into two categories: those that recognized the DENV E domain III and showed complex cross-reactive neutralization activity, and those that recognized domain I/domain II and were more broadly cross-reactive but showed lower neutralization activity. Furthermore, our data in this study is the first to report the efficacy of using PBMCs from acute-phase patients for preparing HuMAbs with strong VN activity against all four DENV serotypes by assay using Vero cells.
- influenza-specific IgG+ memory B cells fell to an average of 1% of all B cells by 14-21 days after vaccination.
- reports show a difference in the B cell phenotype between acute- and convalescent-phase patients with infectious diseases (Leyendeckers et al., Eur J Immunol 29: 1406-1417 (1999)).
- HuMAbs showing neutralizing activity could be obtained in the acute phase.
- VN assay of the HuMAbs obtained in this study classified them into heterogeneous groups: serotype-specific HuMAbs and cross-reactive HuMAbs with two, three, and all four serotypes of DENV. These HuMAbs will also be highly useful as probes to understand the complex mechanisms through which the same antibodies mediate neutralization and ADE of heterologous DENV serotypes. Further epitope mapping studies of these HuMAbs would help shed light on this important issue.
- HuMAbs showed strong neutralization, much higher against all four serotypes of DENV than 4G2 that we used as a positive control of murine anti-DENV E protein.
- these HuMAbs showed ADE activities to DENV-1 to DENV-4 that were much lower than that of 4G2.
- the VN activities of these HuMAbs were similar even when we examined against clinical isolates of DENV-1 to DENV-4 in Thailand.
- Several antibodies showed stronger VN activities than those to the laboratory strains.
- HuMAbs This seems to be derived from the origins for the HuMAbs, the PBMCs from patients who admitted to the Tropical Medicine hospital at Mahidol University from July to August 2010 (Puiprom et al., Biochem Biophys Res Commun 413: 136-142 (2011)).
- the clinical isolates were prepared from patients' blood samples who admitted to the same hospital from 2007 to 2010. Therefore, HuMAbs recognized DENVs that seem to be highly close to the clinical isolates we used in this study.
- the blood specimens (1-8 ml in each) used for cell fusion were collected from 8 infant Thai patients with dengue illness at Pranangklao Hospital (Table 8). The participants were selected based on the clinically diagnosis and results of IgG and IgM levels. The research protocols for human samples were approved by the Ethics Committee of the Department of Medical Sciences, Ministry of Public Health, Thailand.
- SPYMEG (Kubota-Koketsu et al., Biochem Biophys Res Commun 387: 180-185 (2009)) was used as fusion partner cells to develop hybridomas producing specific HuMAbs.
- SPYMEG cells were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 15% of fetal bovine serum (FBS) in a 5% CO 2 incubator at 37 centigrade.
- Vero cells were maintained in Vero cells were maintained in Advanced Dulbecco's modified Eagle medium (Advanced DMEM) with 10% FBS in a 5% CO 2 incubator at 37 centigrade.
- Mosquito-derived cell line C6/36 was maintained in Leibovitz's L-15 medium with 10% FBS and 0.3% tryptose phosphate broth in an incubator at 28 centigrade.
- DENVs used in this study were the 16007 strain of DENV-1, the New Guinea C (NGC) strain of DENV-2, the H87 strain of DENV-3, and the H241 strain of DENV-4.
- the culture supernatants from C6/36 cells infected with individual strains were used as viral stocks.
- Virus titer was estimated as focus-forming unit (FFU), as described previously (Kurosu et al., Biochem Biophys Res Commun 394: 398-404 (2010)).
- the oligonucleotide primer pairs previously reported for serotyping were used for amplification of DENV E gene including most part of domain III: the 1st PCR primers DUL (5'-TGGCTGGTGCACAGACAATGGTT-3' (SEQ. ID NO. 231)) /DUR (5'- GCTGTGTCACCCAGAATGGCCAT-3' (SEQ. ID NO. 232)) that are common to all the serotypes of DENV and the 2nd PCR primers D1L (5'-GGGGCTTCAACATCCCAAGAG-3' (SEQ. ID NO.
- Hybridomas were prepared as follows. About 1-8 milliliters of blood were obtained from individual patients and the PBMCs were prepared by centrifugation through Ficoll-PaqueTM PLUS (GE Healthcare, Uppsala, Sweden) for 40 min at 1,200x g. The PBMCs were fused with SPYMEG cells at a ratio of 10:1 with polyethylene glycol 1500 (Roche Diagnostics Japan, Tokyo, Japan).
- Fused cells were cultured in DMEM supplemented with 15% FBS and 3% BM-condimed (Roche Diagnostics Japan, Tokyo, Japan) in 96-well tissue culture plate for 10 to 14 days in the presence of hypoxanthine-aminopterin-thymidine (HAT; Invitrogen, USA or Sigma Aldrich, USA).
- HAT hypoxanthine-aminopterin-thymidine
- the 1st screening of the culture media for antibody specificity against infected serotype of DENV was performed by indirect immunofluorescent (IF) assay. Wells producing specific antibody were next subjected to cell cloning by limiting dilution. After 10 to 14 days, the 2nd screening was also performed by IF assay.
- the IF assay was performed as follows. Vero cells at 2.0 x 10 4 per well in a 96-well microplate were infected with DENV at MOI 0.5 and the plate were incubated at 37oC, 5% CO 2 . The incubation period for DENV-1 and DENV-2 is 72 hr, and for DENV-3, DENV-4 is 48 hr. After incubation the cells were fixed with 3.7% formaldehyde in phosphate-buffered saline (PBS) at RT for 40-60 min and then perrmeabilized with 1% Triton X-100 in PBS at RT for 10 min. Microplates were washed with PBS 3 times and 50 microlitters of PBS were added to protect cell dehydration.
- PBS phosphate-buffered saline
- VN assay was carried out as follows. The 50 microlitters of undiluted supernatant of hybridoma culture or 2- fold serially diluted purified antibodies from 25 micrograms/ml to 0.20 micrograms/ml, and also advanced DMEM as a negative control, were mixed with 50-100 FFU of individual serotypes of DENV (50 microlitters) and incubated at 37 centigrade, 5% CO 2 for 15 min. Vero cells in a 96-well microplate were then neutralized with the mixture. After inoculation at 37 centigrade for 1 hr 30 min, 100 microlitters of overlay medium (4% CMC mixed with 2x MEM pH 7.0 and 2%FBS, 1% of 200 mMol L-glutamine) was added.
- overlay medium 4% CMC mixed with 2x MEM pH 7.0 and 2%FBS, 1% of 200 mMol L-glutamine
- the plates were empty and washed with PBS and then 50 microlitters of substrate solution [0.1% of 3, 3' DAB (Sigma, USA), 0.4% of 3%H 2 O 2 ) was added and incubated in a dark box at RT. The color reaction was observed under a phase-contrast microscope. The assays were performed in triplicate and the results are expressed as their average.
- the neutralization activity from purified antibodies is expressed as the highest dilution showing more than 50% FFU reduction, compared with the negative control, named VN50.
- the neutralization activity of the culture medium from hybridoma clone is expressed as the percentage of FFU reduction, compared with the negative control.
- Immunoglobulin isotypes/subtypes of antibodies secreted from hybridoma clones were determined by using Bio-Plex ProTM Assays Immunoglobulin Isotyping kit (Bio-Rad, USA). The assay is able to determine IgG1, IgG2, IgG3, IgG4, IgA, IgE and IgM at the same time. The protocol was followed the manufacturer's instruction. Fifty l of culture supernatant from each hybridoma clone, known concentration of standard, and control were added into the well containing magnetic polystyrene color-coded bead labeled with different antibody specifically directed against all immunoglobulin isotypes/subtypes.
- Antibody from each hybridoma clone was determined their specific target against 4 viral antigens, envelop (E), prM (premembrane), NS1, and C (capsid) protein by IF assay.
- Vectors for expression of the DENV-2 prM, E, NS1, C proteins and prM-E fusion were kindly provided from Prof. Kazuyoshi Ikuta Laboratory Osaka University, Japan. All expressed proteins were FLAG fusion proteins.
- the 293T cells were transfected with individual plasmids by using LipofectamineTM reagent (Invitrogen, USA). The transfected cells were used as viral antigens for determination of antibody specificity.
- smear of air-dried cells were made on multispots microscope slides and fixed with acetone containing 40% methanol. The slides can be stored at -80 centigrade until use. Ten microliters of culture supernatant of HuMAbs were placed onto the slides and incubated for 60 min at RT. Slides were washed 3 times with PBS and then stained with FITC- conjugated rabbit anti-human IgG (Dako, Denmark) at dilution of 1:400 for 45 min at RT. After washing to remove unbound protein, the slides were mounted in PBS containing 10% glycerol and specific binding targets were examined under a fluorescent microscope.
- the coding region of H-chain and L-chain of HuMAb were PCR amplified separately using the following primer: 5'-ATG GAC TGG ACC TGG AGG ATC CTC-3' (SEQ. ID NO. 241), 5'-ATG GAC ATA CTT TGT TCC ACG CTC CT-3' (SEQ.
- PCR products were ligated into pGEM T-Easy vector (Promega, Madison, WI) and their sequences were analyzed using a BigDye Terminator v3.1 Cycle Sequencing Kit and ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA).
- the PBMC fractions prepared from patients' blood were applied for the preparation of hybridoma by fusion with SPYMEG cells.
- the culture fluids of individual wells in 96-well microplates in which fused cells were seeded and cultured for 10-14 days in HAT selection medium were subjected to the 1st screening by IF.
- the cells in the wells showing positive signal by IF were next subjected to cell cloning by limiting dilution. After 2 weeks, the culture fluids of the wells containing a single colony were against subjected to the 2nd screening by IF.
- the 43 HuMAbs obtained as mentioned above were characterized their serological reactivity to all 4 DENV serotypes by IF and VN assays.
- the summary of 43 clones with their serological activities is shown in Table 9.
- the IF score and VN activity were varied up to each clone, IF score ranged from negative to 3+ and VN were from 0 to 100%. Examples of IF assay are given in Figure 12.
- IF assay most clones showed cross reactive to all DENV serotypes and IF results could be differentiated into 8 patterns, (I, II, III, IV, V, VI, VII and VIII) as shown in Table 10.
- the 8 infants patients used in this study 3 patients were clinically diagnosed as DHF and 5 patients were diagnosed as DF. All were laboratory confirmed by Dengue IgG and IgM units. PCR serotype of Dengue infection showed negative results for 3 patients with DF. This might come from the small number of virus particles presence in the blood on the first visit day.
- a total of 43 hybridoma clones were obtained as producers of specific HuMAbs against DENV by the use of the PBMCs from 8 infant patients in Thailand.
- the 29 of 43 clones (67.4%) showed cross reaction to all Dengue serotypes by IF assay. Among them, 22 clones showed strong neutralization to all dengue serotypes higher than 80%.
- HuMAbs (DMSc-4, 5, 8, 13, 14, 17, 24, 28, 30, 31, 33, 34, 36, 37, 38, 40, 41) showed >85 neutralization to all DENV serotypes.
- 12 of 17 clones (DMSc- 4, 5, 8, 13, 14, 17, 24, 30, 31, 36, 37, 38,) and 2 clones (DMSc-1,2) previously appeared in provisional patent were completely sequenced.
- the 22 HuMAbs could be candidate for development of therapeutic antibodies.
- these HuMAbs also highly useful as probes to understand the complicate phenomenon how heterogeneous DENV serotypes showing neutralization as well as ADE with the same antibodies. Further studies for epitope mapping of these HuMAbs would be helpful to solve this phenomenon.
Abstract
Description
The present application claims the benefit of U.S. Provisional Patent Application Nos. 61/532,605, filed September 9, 2011, and 61/532,671, filed September 9, 2011, both of which are incorporated herein by reference in their entireties.
The subject matter described herein was supported, at least in part, by the Japan Science and Technology Agency (JST)/Japan International Cooperation Agency (JICA) as part of the Science and Technology Research Partnership for Sustainable Development (SATREPS) and the program of the Founding Research Center for Emerging and Reemerging Infectious Diseases, which was launched through a project commissioned by the Ministry of Education, Cultures, Sports, Science, and Technology of Japan.
1. An anti dengue virus (DENV) monoclonal antibody or an antigen-binding fragment thereof, the monoclonal antibody or the antigen-binding fragment thereof comprising a neutralization activity against serotypes of DENV-1, DENV-2, DENV-3 and DENV-4, wherein the monoclonal antibody comprises a human monoclonal antibody or a humanized monoclonal antibody.
2. An antiDENV human monoclonal antibody according to
3. The antiDENV human monoclonal antibody according to
4. The anti-DENV monoclonal antibody or antigen-binding fragment thereof according to
5. An antidengue virus(DENV) monoclonal antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region any one of (a) to (gg):
(a)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:1 of CDR1, SEQ ID NO:2 of CDR2, and SEQ ID NO:3 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:100 of CDR1, SEQ ID NO:101 of CDR2, and SEQ ID NO:102 of CDR3;
(b)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:4 of CDR1, SEQ ID NO:5 of CDR2, and SEQ ID NO:6 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:103 of CDR1, SEQ ID NO:104 of CDR2, and SEQ ID NO:105 of CDR3;
(c)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:7 of CDR1, SEQ ID NO:8 of CDR2, and SEQ ID NO:9 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:106 of CDR1, SEQ ID NO:107 of CDR2, and SEQ ID NO:108 of CDR3;
(d)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:10 of CDR1, SEQ ID NO:11 of CDR2, and SEQ ID NO:12 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:109 of CDR1, SEQ ID NO:110 of CDR2, and SEQ ID NO:111 of CDR3;
(e)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:13 of CDR1, SEQ ID NO:14 of CDR2, and SEQ ID NO:15 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:112 of CDR1, SEQ ID NO:113 of CDR2, and SEQ ID NO:114 of CDR3;
(f)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:16 of CDR1, SEQ ID NO:17 of CDR2, and SEQ ID NO:18 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:115 of CDR1, SEQ ID NO:116 of CDR2, and SEQ ID NO:117 of CDR3;
(g)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:19 of CDR1, SEQ ID NO:20 of CDR2, and SEQ ID NO:21 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:118 of CDR1, SEQ ID NO:119 of CDR2, and SEQ ID NO:120 of CDR3;
(h)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:22 of CDR1, SEQ ID NO:23 of CDR2, and SEQ ID NO:24 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:121 of CDR1, SEQ ID NO:122 of CDR2, and SEQ ID NO:123 of CDR3;
(i)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:25 of CDR1, SEQ ID NO:26 of CDR2, and SEQ ID NO:27 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:124 of CDR1, SEQ ID NO:125 of CDR2, and SEQ ID NO:126 of CDR3;
(j)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:28 of CDR1, SEQ ID NO:29 of CDR2, and SEQ ID NO:30 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:127 of CDR1, SEQ ID NO:128 of CDR2, and SEQ ID NO:129 of CDR3;
(k)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:31 of CDR1, SEQ ID NO:32 of CDR2, and SEQ ID NO:33 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:130 of CDR1, SEQ ID NO:131 of CDR2, and SEQ ID NO:132 of CDR3;
(l)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:34 of CDR1, SEQ ID NO:35 of CDR2, and SEQ ID NO:36 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:133 of CDR1, SEQ ID NO:134 of CDR2, and SEQ ID NO:135 of CDR3;
(m)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:37 of CDR1, SEQ ID NO:38 of CDR2, and SEQ ID NO:39 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:136 of CDR1, SEQ ID NO:137 of CDR2, and SEQ ID NO:138 of CDR3;
(n)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:40 of CDR1, SEQ ID NO:41 of CDR2, and SEQ ID NO:42 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:139 of CDR1, SEQ ID NO:140 of CDR2, and SEQ ID NO:141 of CDR3;
(o)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:43 of CDR1, SEQ ID NO:44 of CDR2, and SEQ ID NO:45 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:142 of CDR1, SEQ ID NO:143 of CDR2, and SEQ ID NO:144 of CDR3;
(p)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:46 of CDR1, SEQ ID NO:47 of CDR2, and SEQ ID NO:48 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:145 of CDR1, SEQ ID NO:146 of CDR2, and SEQ ID NO:147 of CDR3;
(q)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:49 of CDR1, SEQ ID NO:50 of CDR2, and SEQ ID NO:51 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:148 of CDR1, SEQ ID NO:149 of CDR2, and SEQ ID NO:150 of CDR3;
(r)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:52 of CDR1, SEQ ID NO:53 of CDR2, and SEQ ID NO:54 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:151 of CDR1, SEQ ID NO:152 of CDR2, and SEQ ID NO:153 of CDR3;
(s)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:55 of CDR1, SEQ ID NO:56 of CDR2, and SEQ ID NO:57 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:154 of CDR1, SEQ ID NO:155 of CDR2, and SEQ ID NO:156 of CDR3;
(t)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:58 of CDR1, SEQ ID NO:59 of CDR2, and SEQ ID NO:60 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:157 of CDR1, SEQ ID NO:158 of CDR2, and SEQ ID NO:159 of CDR3;
(u)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:61 of CDR1, SEQ ID NO:62 of CDR2, and SEQ ID NO:63 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:160 of CDR1, SEQ ID NO:161 of CDR2, and SEQ ID NO:162 of CDR3;
(v)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:64 of CDR1, SEQ ID NO:65 of CDR2, and SEQ ID NO:66 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:163 of CDR1, SEQ ID NO:164 of CDR2, and SEQ ID NO:165 of CDR3;
(x)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:70 of CDR1, SEQ ID NO:71 of CDR2, and SEQ ID NO:72 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:169 of CDR1, SEQ ID NO:170 of CDR2, and SEQ ID NO:171 of CDR3;
(y)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:73 of CDR1, SEQ ID NO:74 of CDR2, and SEQ ID NO:75 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:172 of CDR1, SEQ ID NO:173 of CDR2, and SEQ ID NO:174 of CDR3;
(z)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:76 of CDR1, SEQ ID NO:77 of CDR2, and SEQ ID NO:78 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:175 of CDR1, SEQ ID NO:176 of CDR2, and SEQ ID NO:177 of CDR3;
(aa)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:79 of CDR1, SEQ ID NO:80 of CDR2, and SEQ ID NO:81 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:178 of CDR1, SEQ ID NO:179 of CDR2, and SEQ ID NO:180 of CDR3;
(bb)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:82 of CDR1, SEQ ID NO:83 of CDR2, and SEQ ID NO:84 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:181 of CDR1, SEQ ID NO:182 of CDR2, and SEQ ID NO:183 of CDR3;
(cc)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:85 of CDR1, SEQ ID NO:86 of CDR2, and SEQ ID NO:87 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:184 of CDR1, SEQ ID NO:185 of CDR2, and SEQ ID NO:186 of CDR3;
(dd)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:88 of CDR1, SEQ ID NO:89 of CDR2, and SEQ ID NO:90 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:187 of CDR1, SEQ ID NO:188 of CDR2, and SEQ ID NO:189 of CDR3;
(ee)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:91 of CDR1, SEQ ID NO:92 of CDR2, and SEQ ID NO:93 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:190 of CDR1, SEQ ID NO:191 of CDR2, and SEQ ID NO:192 of CDR3;
(ff)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:94 of CDR1, SEQ ID NO:95 of CDR2, and SEQ ID NO:96 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:193 of CDR1, SEQ ID NO:194 of CDR2, and SEQ ID NO:195 of CDR3;
(gg)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:97 of CDR1, SEQ ID NO:98 of CDR2, and SEQ ID NO:99 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:196 of CDR1, SEQ ID NO:197 of CDR2, and SEQ ID NO:198 of CDR3;
, wherein the monoclonal antibody comprises a human monoclonal antibody or a humanized monoclonal antibody.
6. The antiDENV human monoclonal antibody according to
7. A method for producing an antidengue virus (DENV) human monoclonal antibody comprising:
1)producing a hybridoma by fusing a peripheral blood mononuclear cell (PBMC) from a patient in an acute phase of DENV infection with a fusion partner cell capable of efficient cell fusion;
2)obtaining an anti-DENV human monoclonal antibody from the hybridoma.
8. A method for producing an antiDENV human monoclonal antibody according to
9. A method for producing a hybridoma comprising fusing a peripheral blood mononuclear cell (PBMC) from a patient in an acute phase of dengue virus (DENV) infection with a fusion partner cell capable of efficient cell fusion.
10. The method for producing hybridoma according to
11. The method for producing a hybridoma according to
2. An antiDENV human monoclonal antibody according to
3. The antiDENV human monoclonal antibody according to
4. The anti-DENV monoclonal antibody or antigen-binding fragment thereof according to
5. An antidengue virus(DENV) monoclonal antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region any one of (a) to (gg):
(a)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:1 of CDR1, SEQ ID NO:2 of CDR2, and SEQ ID NO:3 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:100 of CDR1, SEQ ID NO:101 of CDR2, and SEQ ID NO:102 of CDR3;
(b)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:4 of CDR1, SEQ ID NO:5 of CDR2, and SEQ ID NO:6 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:103 of CDR1, SEQ ID NO:104 of CDR2, and SEQ ID NO:105 of CDR3;
(c)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:7 of CDR1, SEQ ID NO:8 of CDR2, and SEQ ID NO:9 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:106 of CDR1, SEQ ID NO:107 of CDR2, and SEQ ID NO:108 of CDR3;
(d)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:10 of CDR1, SEQ ID NO:11 of CDR2, and SEQ ID NO:12 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:109 of CDR1, SEQ ID NO:110 of CDR2, and SEQ ID NO:111 of CDR3;
(e)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:13 of CDR1, SEQ ID NO:14 of CDR2, and SEQ ID NO:15 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:112 of CDR1, SEQ ID NO:113 of CDR2, and SEQ ID NO:114 of CDR3;
(f)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:16 of CDR1, SEQ ID NO:17 of CDR2, and SEQ ID NO:18 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:115 of CDR1, SEQ ID NO:116 of CDR2, and SEQ ID NO:117 of CDR3;
(g)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:19 of CDR1, SEQ ID NO:20 of CDR2, and SEQ ID NO:21 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:118 of CDR1, SEQ ID NO:119 of CDR2, and SEQ ID NO:120 of CDR3;
(h)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:22 of CDR1, SEQ ID NO:23 of CDR2, and SEQ ID NO:24 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:121 of CDR1, SEQ ID NO:122 of CDR2, and SEQ ID NO:123 of CDR3;
(i)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:25 of CDR1, SEQ ID NO:26 of CDR2, and SEQ ID NO:27 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:124 of CDR1, SEQ ID NO:125 of CDR2, and SEQ ID NO:126 of CDR3;
(j)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:28 of CDR1, SEQ ID NO:29 of CDR2, and SEQ ID NO:30 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:127 of CDR1, SEQ ID NO:128 of CDR2, and SEQ ID NO:129 of CDR3;
(k)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:31 of CDR1, SEQ ID NO:32 of CDR2, and SEQ ID NO:33 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:130 of CDR1, SEQ ID NO:131 of CDR2, and SEQ ID NO:132 of CDR3;
(l)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:34 of CDR1, SEQ ID NO:35 of CDR2, and SEQ ID NO:36 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:133 of CDR1, SEQ ID NO:134 of CDR2, and SEQ ID NO:135 of CDR3;
(m)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:37 of CDR1, SEQ ID NO:38 of CDR2, and SEQ ID NO:39 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:136 of CDR1, SEQ ID NO:137 of CDR2, and SEQ ID NO:138 of CDR3;
(n)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:40 of CDR1, SEQ ID NO:41 of CDR2, and SEQ ID NO:42 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:139 of CDR1, SEQ ID NO:140 of CDR2, and SEQ ID NO:141 of CDR3;
(o)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:43 of CDR1, SEQ ID NO:44 of CDR2, and SEQ ID NO:45 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:142 of CDR1, SEQ ID NO:143 of CDR2, and SEQ ID NO:144 of CDR3;
(p)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:46 of CDR1, SEQ ID NO:47 of CDR2, and SEQ ID NO:48 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:145 of CDR1, SEQ ID NO:146 of CDR2, and SEQ ID NO:147 of CDR3;
(q)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:49 of CDR1, SEQ ID NO:50 of CDR2, and SEQ ID NO:51 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:148 of CDR1, SEQ ID NO:149 of CDR2, and SEQ ID NO:150 of CDR3;
(r)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:52 of CDR1, SEQ ID NO:53 of CDR2, and SEQ ID NO:54 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:151 of CDR1, SEQ ID NO:152 of CDR2, and SEQ ID NO:153 of CDR3;
(s)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:55 of CDR1, SEQ ID NO:56 of CDR2, and SEQ ID NO:57 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:154 of CDR1, SEQ ID NO:155 of CDR2, and SEQ ID NO:156 of CDR3;
(t)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:58 of CDR1, SEQ ID NO:59 of CDR2, and SEQ ID NO:60 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:157 of CDR1, SEQ ID NO:158 of CDR2, and SEQ ID NO:159 of CDR3;
(u)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:61 of CDR1, SEQ ID NO:62 of CDR2, and SEQ ID NO:63 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:160 of CDR1, SEQ ID NO:161 of CDR2, and SEQ ID NO:162 of CDR3;
(v)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:64 of CDR1, SEQ ID NO:65 of CDR2, and SEQ ID NO:66 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:163 of CDR1, SEQ ID NO:164 of CDR2, and SEQ ID NO:165 of CDR3;
(x)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:70 of CDR1, SEQ ID NO:71 of CDR2, and SEQ ID NO:72 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:169 of CDR1, SEQ ID NO:170 of CDR2, and SEQ ID NO:171 of CDR3;
(y)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:73 of CDR1, SEQ ID NO:74 of CDR2, and SEQ ID NO:75 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:172 of CDR1, SEQ ID NO:173 of CDR2, and SEQ ID NO:174 of CDR3;
(z)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:76 of CDR1, SEQ ID NO:77 of CDR2, and SEQ ID NO:78 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:175 of CDR1, SEQ ID NO:176 of CDR2, and SEQ ID NO:177 of CDR3;
(aa)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:79 of CDR1, SEQ ID NO:80 of CDR2, and SEQ ID NO:81 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:178 of CDR1, SEQ ID NO:179 of CDR2, and SEQ ID NO:180 of CDR3;
(bb)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:82 of CDR1, SEQ ID NO:83 of CDR2, and SEQ ID NO:84 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:181 of CDR1, SEQ ID NO:182 of CDR2, and SEQ ID NO:183 of CDR3;
(cc)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:85 of CDR1, SEQ ID NO:86 of CDR2, and SEQ ID NO:87 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:184 of CDR1, SEQ ID NO:185 of CDR2, and SEQ ID NO:186 of CDR3;
(dd)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:88 of CDR1, SEQ ID NO:89 of CDR2, and SEQ ID NO:90 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:187 of CDR1, SEQ ID NO:188 of CDR2, and SEQ ID NO:189 of CDR3;
(ee)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:91 of CDR1, SEQ ID NO:92 of CDR2, and SEQ ID NO:93 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:190 of CDR1, SEQ ID NO:191 of CDR2, and SEQ ID NO:192 of CDR3;
(ff)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:94 of CDR1, SEQ ID NO:95 of CDR2, and SEQ ID NO:96 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:193 of CDR1, SEQ ID NO:194 of CDR2, and SEQ ID NO:195 of CDR3;
(gg)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:97 of CDR1, SEQ ID NO:98 of CDR2, and SEQ ID NO:99 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:196 of CDR1, SEQ ID NO:197 of CDR2, and SEQ ID NO:198 of CDR3;
, wherein the monoclonal antibody comprises a human monoclonal antibody or a humanized monoclonal antibody.
6. The antiDENV human monoclonal antibody according to
7. A method for producing an antidengue virus (DENV) human monoclonal antibody comprising:
1)producing a hybridoma by fusing a peripheral blood mononuclear cell (PBMC) from a patient in an acute phase of DENV infection with a fusion partner cell capable of efficient cell fusion;
2)obtaining an anti-DENV human monoclonal antibody from the hybridoma.
8. A method for producing an antiDENV human monoclonal antibody according to
9. A method for producing a hybridoma comprising fusing a peripheral blood mononuclear cell (PBMC) from a patient in an acute phase of dengue virus (DENV) infection with a fusion partner cell capable of efficient cell fusion.
10. The method for producing hybridoma according to
11. The method for producing a hybridoma according to
Kuhn RJ, Zhang W, Rossmann MG, Platnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strause EG, Baker TS, Strauss JH (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108: 717-725.
Innis BL, Thirawuth V, Hemachudha C (1989) Identification of continuous epitopes of the envelope glycoprotein of
Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, Brandt WE (1989) Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol 70: 37-43.
Braciale TJ, Hahn YS, Burton DR (2006) The adaptive immune response to viruses. In Fields Virology, pp. 279-325. Edited by Knipe DM, Howley PM, Griffin DE, Lamb RA. 5th edition. Lippincott Williams & Wilkins.
van der Schaar HM, Wilschut JC, Smit JM (2009) Role of antibodies in controlling dengue virus infection. Immunobiology 214: 613-629.
Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead SB (1984) Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120: 653-669.
Halstead SB, O'Rourke EJ (1977) Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146: 201-217.
Diamond MS, Pierson TC, Fremont DH (2008) The structural immunology of antibody protection against West Nile virus. Immunol Rev 225: 212-225.
Reiter P (2010) Yellow fever and dengue: a threat to Europe EuroSurveill 15: 19509.
Garcia G, Sierra B, Perez AB, Aguirre E, Rosado I, Gonzalez N, Izquierdo A, Pupo M, Diaz DRD, Sanchez L, Marcheco B, Hirayama K, Guzman MG (2010) Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the Fc RIIa polymorphism. Am J Trop Med Hyg 82: 1153-1156.
Harris E, Videa E, Perez L, Sandoval E, Tellez Y, Perez ML, Cuadra R, Rocha J, Idiaquez W, Alonso RE, Delgado MA, Campo LA, Acevedo F, Gonzalez A, Amador JJ, Balmaseda A (2000) Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. Am J Trop Med Hyg 63: 5-11.
Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitegead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F (2010) The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8: 271-283.
Wahala WMPB, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM (2009) Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392: 103-113.
Schieffelin JS, Costin JM, Nicholson CO, Orgeron NM, Fontaine KA, Isern S, Michael SF, Robinson JE (2010) Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J 7: 28.
Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science 328: 745-748.
de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WMPB, Kraus A, Olivarez NP, Pham Q, Brian J, Tsai W-Y, Wang W-K, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM (2011) In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5: e1188.
Smith SA, Zhou Y, Olivarez NP. Broadwater AH, de Silva AM, Crowe JE, Jr (2012) Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol 86: 2665-2675.
de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WMPB, White LJ, Diamond MS, Baric RS, Crowe JE, Jr (2012) Identification of human neutralizing antibodies that bind to complex epitope on dengue virions. Proc Natl Acad Sci USA (2012) 109:7439-7444.
Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, Yip A, Schul W, Aung M, Kostyuchenko VA, Leo YS, Chan SH, Smith KG, Chan AH, Zou G, Ooi EE, Kemeny DM, Tan GK, Ng JK, Ng ML, Alonso S, Fisher D, Shi PY, Hanson BJ, Lok SM, Macary PA (2012) The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci TM 4: 139ra83.
Zou G, Kukkaro P, Lok S-M, Ng JKW, Tan GK, Hanson BJ, Alonso S, MacAry PA, Shi P-Y (2012) Resistance analysis of an antibody that selectively inhibits dengue virus serotype-1. Antiviral Res 95: 216-223 2012.
Setthapramote C, Sasaki T, Puiprom O, Limkittikul K, Pitaksajjakul P, Pipattanaboon C, Sasayama M, Leuangwutiwong P, Phumratanaprapin W, Chamnachanan S, Kusolsuk T, Jittmittraphap A, Asai A, Arias JF, Hirai I, Kuhara M, Okuno Y, Kurosu T, Ramasoota P, Ikuta K (2012) Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection. Biochem Biophy Res Commun 423: 867-872.
Kozbor D, Roder JC (1981) Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique. J Immunol 127: 1275-1280.
Steinitz M, Tamir S, Frodin JE, Lefvert AK, Mellstedt H (1988) Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies. J Immunol 141: 3516-3522.
Lanzavecchia A, Corti D, Sallusto F (2007) Human monoclonal antibodies by immortalization of memory B cells. Curr Opin Biotechnol 18: 523-528.
Kozbor D, Lagarde AE, Roder JC (1982) Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines. Proc Natl Acad Sci USA 79: 6651-6655.
Karpas A, Dremucheva A, Czepulkowski BH (1998) A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc Natl Acad Sci USA 98: 1799-1804.
Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522-525.
McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348: 552-554.
Green LL (1999) Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 231: 11-23.
Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10: 871-875.
Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, Hien TT, Sallusto F, Ha do Q, Farrar J, de Jong MD, Lanzavecchia A, Subbarao K (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 4: e178.
Frank AL, Six HR, Marchini A (1989) Human monoclonal antibodies to influenza virus: IgG subclass and light chain distribution. Viral Immunol 2: 31-36.
Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng N-Y, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453: 667-671.
Kubota-Koketsu R, Mizuta H, Oshita M, Ideno S, Yunoki M, Kuhara M, Yamamoto N, Okuno Y, Ikuta K (2009) Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors. Biochem Biophys Res Commun 387: 180-185.
Halstead SB (2008) Dengue virus-mosquito interactions. Annu Rev Entomol 53: 273-291.
Kurosu T, Khamlert C, Phanthanawiboon S, Ikuta K, Anatapreecha S (2010) Highly efficient rescue of dengue virus using a co-culture system with mosquito/mammalian cells. Biochem Biophys Res Commun 394: 398-404.
Yenchitsomanus P, Sricharoen P, Jaruthasana I, Pattanakitsakul S, Nitayaphan S, Mongkolsapaya J, Malasit P (1996) Rapid detection and identification of dengue viruses by polymerase chain reaction (PCR). Southeast Asian J Trop Med Public Health 27: 228-236.
Falconar AKI (1999) Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch Virol 144: 2313-2330.
Okuno Y, Igarashi A, Fukai K (1978) Neutralization tests fro dengue and Japanese encephalitis viruses by the focus reduction method using peroxidase-anti-peroxidase staining. Biken J 21: 137-147.
Klassen CD (1991) Principles of Toxicology. In Pharmacological Basis of Therapeutics, pp. 49-61. Edited by Gilman AG, Tall TW, Nies AS, Taylor P. 8th edition. McGraw-Hill.
Kurosu T, Chaichana P, Yamate M, Anantapreecha S, Ikuta K (2007) Secreted complement regulatory protein clusterin interacts with dengue virus
Shu PY, Chang SF, Kuo YC, Yueh YY, Chien LJ, Sue CL, Lin TH, Huang JH (2003) Development of group- and serotype-specific one-step SYBR green I-based real-time reverse transcription-PCR assay for dengue virus. J Clin Microbiol. 41:2408-2416.
Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. comparative C(T) method. Nat Protoc 3:1101-1108
Marasco WA, Sui J (2007) The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotech 25: 1421-1434.
Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, Loeb M, Throsby M, Fremont DH, Pierson TC, Diamond MS (2007) Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 81: 11828-11839.
Leyendeckers H, Odendahl M, Lohndorf A, Irsch J, Spangfort M, Miltenyi S, Hunzelmann N, Assenmacher M, Radbruch A, Schmitz J (1999) Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG. Eur J Immunol 29: 1406-1417.
Puiprom O, Yamashita A, Sasayama M, Limkittikul K, Boonha K, Jittmitraphap A, Leaungwutiwong P, Kurosu T, Ramasoota P, Ikuta K (2011) Co-existence of major and minor viral populations from two different origins in patients secondarily infected with
Bernardo L, Fleitas O, Pavon A, Hermida L, Guillen G, Guzman MG (2009) Antibodies induced by
Zompi S, Harris E (2012) Animal models of dengue virus infection. Viruses 4:62-82.
Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS (2010) Structure and function analysis of therapeutic monoclonal antibodies against
Omatsu T, Moi ML, Hirayama T, Takasaki T, Nakamura S, Tajima S, Ito M, Yoshida T, Saito A, Katakai Y, Akari H, Kurane I (2011) Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity. J Gen Virol 92: 2272-2280.
Omatsu T, MOi ML, Takasaki T, Nakamura S, Katakai Y, Tanjima S, Ito M, Yoshida T, Saito A, Akari H, Kurane I (2012) Changes in hematological and serum biochemical parameters in common marmosets (Callithrix jacchus) after inoculation with dengue virus J Med Primatol, in press.
Innis BL, Thirawuth V, Hemachudha C (1989) Identification of continuous epitopes of the envelope glycoprotein of
Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, Brandt WE (1989) Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol 70: 37-43.
Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, Salitul V, Phanthumachinda B, Halstead SB. (1984) Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120: 653-669.
Halstead SB, O'Rourke EJ (1977) Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146: 201-217.
Diamond MS, Pierson TC, Fremont DH (2008) The structural immunology of antibody protection against West Nile virus. Immunol Rev 225: 212-225.
Harris E, Videa E, Perez L, Sandoval E, Tellez Y, Perez ML, Cuadra R, Rocha J, Idiaquez W, Alonso RE, Delgado MA, Campo LA, Acevedo F, Gonzalez A, Amador JJ, Balmaseda A (2000) Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua. Am J Trop Med Hyg 63: 5-11.
Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Roco-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS (2010) Structural and function analysis of therapeutic monoclonal antibodies against
Goncalvez AP, Men R, Wernly C, Purcell RH, Lai CJ (2004) Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently
Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC (2005) Monoclonal antibody successes in the clinic. Nat Biotechnol 23: 1073-1078.
Frogel MP, Stewart DL, Hoopes M, Femandes AW, Mahadevia PJ (2010) A systematic review of compliance with Pilivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm 16: 46-58.
Mansbach J, Kunz S, Acholonu U, Clark S, Camargo CA Jr (2007) Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis. Pediatr Emerg Care 23: 362-367.
Kozbor D, Roder JC (1981) Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique. J Immunol 127: 1275-1280.
Steinitz M, Tamir S, Frodin JE, Lefvert AK, Mellstedt H (1988) Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies. J Immunol 141: 3516-3522.
Lanzavecchia A, Corti D, Sallusto F (2007) Human monoclonal antibodies by immortalization of memory B cells. 2007. Curr Opin Biotechnol 18: 523-528.
Kozbor D, Lagarde AE, Roder JC (1982) Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines. Proc Natl Acad Sci U S A 79: 6651-6655.
Karpas A, Dremucheva A, Czepulkowski BH (1998) A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc Natl Acad Sci U S A 98: 1799-1804.
Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321: 522-525.
McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348: 552-554.
Green LL (1999) Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 231: 11-23.
Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10: 871-875.
Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, Hien TT, Sallusto F, Ha do Q, Farrar J, de Jong MD, Lanzavecchia A, Subbarao K (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 4: e178.
Frank AL, Six HR, Marchini A (1989) Human monoclonal antibodies to influenza virus: IgG subclass and light chain distribution. Viral Immunol 2: 31-36.
Schieffelin JS, Costin JM, Nicholson CO, Orgeron NM, Fontaine KA, Isern S, Michael SF, Robinson JE (2010) Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J 7: 28.
Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G (2010) Cross-reacting antibodies enhance dengue virus infection in humans. Science 328: 745-748.
Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitegead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F (2010) The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8: 271-283.
de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WMPB, Kraus A, Olivarez NP, Pham Q, Brian J, Tsai W-Y, Wang W-K, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM (2011) In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS NTG 5: e1188.
Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng N-Y, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453: 667-671.
Kubota-Koketsu R, Mizuta H, Oshita M, Ideno S, Yunoki M, Kuhara M, Yamamoto N, Okuno Y, Ikuta K (2009) Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors. Biochem Biophys Res Commun 387: 180-185.
Kurosu T, Khamlert C, Phanthanawiboon S, Ikuta Km Anatapreecha S (2010) Highly efficient rescue of dengue virus using a co-culture system with mosquito/mammalian cells. Biochem Biophys Res Commun 394: 398-404.
Yenchitsomanus P, Sricharoen P, Jaruthasana I, Pattanakitsakul S, Nitayaphan S, Mongkolsapaya J, Malasit P (1996) Rapid detection and identification of dengue viruses by polymerase chain reaction (PCR). Southeast Asian J Trop Med Public Health 27: 228-236.
Falconar AKI (1999) Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch Virol 144: 2313-2330.
Claims (11)
- An anti dengue virus (DENV) monoclonal antibody or an antigen-binding fragment thereof, the monoclonal antibody or the antigen-binding fragment thereof comprising a neutralization activity against serotypes of DENV-1, DENV-2, DENV-3 and DENV-4, wherein the monoclonal antibody comprises a human monoclonal antibody or a humanized monoclonal antibody.
- An antiDENV human monoclonal antibody according to claim 1, wherein the human monoclonal antibody is produced by a hybridoma made by fusing a peripheral blood mononuclear cell (PBMC) from a patient in an acute phase of DENV infection with a fusion partner cell capable of efficient cell fusion.
- The antiDENV human monoclonal antibody according to claim 2, wherein the fusion partner cell is a SPYMEG cell.
- The anti-DENV monoclonal antibody or antigen-binding fragment thereof according to claim 1 comprising an IgG, a Fab, a Fab', a F(ab')2, a scFv, or a dsFv.
- An antidengue virus(DENV) monoclonal antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region of (a) to (gg):
(a)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:1 of CDR1, SEQ ID NO:2 of CDR2, and SEQ ID NO:3 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:100 of CDR1, SEQ ID NO:101 of CDR2, and SEQ ID NO:102 of CDR3;
(b)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:4 of CDR1, SEQ ID NO:5 of CDR2, and SEQ ID NO:6 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:103 of CDR1, SEQ ID NO:104 of CDR2, and SEQ ID NO:105 of CDR3;
(c)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:7 of CDR1, SEQ ID NO:8 of CDR2, and SEQ ID NO:9 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:106 of CDR1, SEQ ID NO:107 of CDR2, and SEQ ID NO:108 of CDR3;
(d)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:10 of CDR1, SEQ ID NO:11 of CDR2, and SEQ ID NO:12 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:109 of CDR1, SEQ ID NO:110 of CDR2, and SEQ ID NO:111 of CDR3;
(e)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:13 of CDR1, SEQ ID NO:14 of CDR2, and SEQ ID NO:15 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:112 of CDR1, SEQ ID NO:113 of CDR2, and SEQ ID NO:114 of CDR3;
(f)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:16 of CDR1, SEQ ID NO:17 of CDR2, and SEQ ID NO:18 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:115 of CDR1, SEQ ID NO:116 of CDR2, and SEQ ID NO:117 of CDR3;
(g)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:19 of CDR1, SEQ ID NO:20 of CDR2, and SEQ ID NO:21 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:118 of CDR1, SEQ ID NO:119 of CDR2, and SEQ ID NO:120 of CDR3;
(h)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:22 of CDR1, SEQ ID NO:23 of CDR2, and SEQ ID NO:24 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:121 of CDR1, SEQ ID NO:122 of CDR2, and SEQ ID NO:123 of CDR3;
(i)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:25 of CDR1, SEQ ID NO:26 of CDR2, and SEQ ID NO:27 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:124 of CDR1, SEQ ID NO:125 of CDR2, and SEQ ID NO:126 of CDR3;
(j)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:28 of CDR1, SEQ ID NO:29 of CDR2, and SEQ ID NO:30 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:127 of CDR1, SEQ ID NO:128 of CDR2, and SEQ ID NO:129 of CDR3;
(k)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:31 of CDR1, SEQ ID NO:32 of CDR2, and SEQ ID NO:33 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:130 of CDR1, SEQ ID NO:131 of CDR2, and SEQ ID NO:132 of CDR3;
(l)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:34 of CDR1, SEQ ID NO:35 of CDR2, and SEQ ID NO:36 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:133 of CDR1, SEQ ID NO:134 of CDR2, and SEQ ID NO:135 of CDR3;
(m)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:37 of CDR1, SEQ ID NO:38 of CDR2, and SEQ ID NO:39 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:136 of CDR1, SEQ ID NO:137 of CDR2, and SEQ ID NO:138 of CDR3;
(n)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:40 of CDR1, SEQ ID NO:41 of CDR2, and SEQ ID NO:42 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:139 of CDR1, SEQ ID NO:140 of CDR2, and SEQ ID NO:141 of CDR3;
(o)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:43 of CDR1, SEQ ID NO:44 of CDR2, and SEQ ID NO:45 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:142 of CDR1, SEQ ID NO:143 of CDR2, and SEQ ID NO:144 of CDR3;
(p)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:46 of CDR1, SEQ ID NO:47 of CDR2, and SEQ ID NO:48 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:145 of CDR1, SEQ ID NO:146 of CDR2, and SEQ ID NO:147 of CDR3;
(q)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:49 of CDR1, SEQ ID NO:50 of CDR2, and SEQ ID NO:51 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:148 of CDR1, SEQ ID NO:149 of CDR2, and SEQ ID NO:150 of CDR3;
(r)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:52 of CDR1, SEQ ID NO:53 of CDR2, and SEQ ID NO:54 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:151 of CDR1, SEQ ID NO:152 of CDR2, and SEQ ID NO:153 of CDR3;
(s)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:55 of CDR1, SEQ ID NO:56 of CDR2, and SEQ ID NO:57 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:154 of CDR1, SEQ ID NO:155 of CDR2, and SEQ ID NO:156 of CDR3;
(t)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:58 of CDR1, SEQ ID NO:59 of CDR2, and SEQ ID NO:60 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:157 of CDR1, SEQ ID NO:158 of CDR2, and SEQ ID NO:159 of CDR3;
(u)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:61 of CDR1, SEQ ID NO:62 of CDR2, and SEQ ID NO:63 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:160 of CDR1, SEQ ID NO:161 of CDR2, and SEQ ID NO:162 of CDR3;
(v)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:64 of CDR1, SEQ ID NO:65 of CDR2, and SEQ ID NO:66 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:163 of CDR1, SEQ ID NO:164 of CDR2, and SEQ ID NO:165 of CDR3;
(x)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:70 of CDR1, SEQ ID NO:71 of CDR2, and SEQ ID NO:72 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:169 of CDR1, SEQ ID NO:170 of CDR2, and SEQ ID NO:171 of CDR3;
(y)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:73 of CDR1, SEQ ID NO:74 of CDR2, and SEQ ID NO:75 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:172 of CDR1, SEQ ID NO:173 of CDR2, and SEQ ID NO:174 of CDR3;
(z)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:76 of CDR1, SEQ ID NO:77 of CDR2, and SEQ ID NO:78 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:175 of CDR1, SEQ ID NO:176 of CDR2, and SEQ ID NO:177 of CDR3;
(aa)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:79 of CDR1, SEQ ID NO:80 of CDR2, and SEQ ID NO:81 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:178 of CDR1, SEQ ID NO:179 of CDR2, and SEQ ID NO:180 of CDR3;
(bb)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:82 of CDR1, SEQ ID NO:83 of CDR2, and SEQ ID NO:84 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:181 of CDR1, SEQ ID NO:182 of CDR2, and SEQ ID NO:183 of CDR3;
(cc)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:85 of CDR1, SEQ ID NO:86 of CDR2, and SEQ ID NO:87 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:184 of CDR1, SEQ ID NO:185 of CDR2, and SEQ ID NO:186 of CDR3;
(dd)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:88 of CDR1, SEQ ID NO:89 of CDR2, and SEQ ID NO:90 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:187 of CDR1, SEQ ID NO:188 of CDR2, and SEQ ID NO:189 of CDR3;
(ee)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:91 of CDR1, SEQ ID NO:92 of CDR2, and SEQ ID NO:93 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:190 of CDR1, SEQ ID NO:191 of CDR2, and SEQ ID NO:192 of CDR3;
(ff)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:94 of CDR1, SEQ ID NO:95 of CDR2, and SEQ ID NO:96 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:193 of CDR1, SEQ ID NO:194 of CDR2, and SEQ ID NO:195 of CDR3;
(gg)a first amino acid sequence of a complementarity-determining region (CDR) of the heavy chain variable region comprising SEQ ID NO:97 of CDR1, SEQ ID NO:98 of CDR2, and SEQ ID NO:99 of CDR3; and
a second amino acid sequence of a CDR of the light chain variable region comprising SEQ ID NO:196 of CDR1, SEQ ID NO:197 of CDR2, and SEQ ID NO:198 of CDR3;
, wherein the monoclonal antibody comprises a human monoclonal antibody or a humanized monoclonal antibody. - The antiDENV human monoclonal antibody according to claim 5 comprising an IgG, a Fab, a Fab', a F(ab')2, a scFv, or a dsFv.
- A method for producing an antidengue virus (DENV) human monoclonal antibody comprising:
1)producing a hybridoma by fusing a peripheral blood mononuclear cell (PBMC) from a patient in an acute phase of DENV infection with a fusion partner cell capable of efficient cell fusion;
2)obtaining an anti-DENV human monoclonal antibody from the hybridoma. - A method for producing an antiDENV human monoclonal antibody according to claim 7, wherein the fusion partner cell is a SPYMEG cell.
- A method for producing a hybridoma comprising fusing a peripheral blood mononuclear cell (PBMC) from a patient in an acute phase of dengue virus (DENV) infection with a fusion partner cell capable of efficient cell fusion.
- The method for producing hybridoma according to claim 9, wherein the fusion partner cell is a SPYMEG cell.
- The method for producing a hybridoma according to claim 9, wherein an antiDENV human monoclonal antibody obtained from the hybridoma comprises a neutralization activity against serotypes of DENV-1, DENV-2, DENV-3 and DENV-4.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2012305807A AU2012305807B2 (en) | 2011-09-09 | 2012-09-07 | Dengue-virus serotype neutralizing antibodies |
SG11201400100SA SG11201400100SA (en) | 2011-09-09 | 2012-09-07 | Dengue-virus serotype neutralizing antibodies |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161532671P | 2011-09-09 | 2011-09-09 | |
US201161532605P | 2011-09-09 | 2011-09-09 | |
US61/532,671 | 2011-09-09 | ||
US61/532,605 | 2011-09-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013035345A2 true WO2013035345A2 (en) | 2013-03-14 |
WO2013035345A3 WO2013035345A3 (en) | 2013-09-06 |
Family
ID=47116163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/005699 WO2013035345A2 (en) | 2011-09-09 | 2012-09-07 | Dengue-virus serotype neutralizing antibodies |
Country Status (4)
Country | Link |
---|---|
AU (1) | AU2012305807B2 (en) |
MY (1) | MY170725A (en) |
SG (1) | SG11201400100SA (en) |
WO (1) | WO2013035345A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015122995A1 (en) | 2014-02-11 | 2015-08-20 | Visterra, Inc. | Antibody moleules to dengue virus and uses thereof |
CN105004860A (en) * | 2015-07-24 | 2015-10-28 | 烟台昊清生物科技有限公司 | Florfenicol rapid detection kit and preparation and use method thereof |
CN105137068A (en) * | 2015-07-24 | 2015-12-09 | 烟台昊清生物科技有限公司 | Florfenicol on-site test paper, and preparation and use methods thereof |
WO2017165736A1 (en) | 2016-03-25 | 2017-09-28 | Visterra, Inc. | Formulation of antibody molecules to dengue virus |
CN109929033A (en) * | 2019-03-15 | 2019-06-25 | 中国人民解放军军事科学院军事医学研究院 | A kind of human antibody specifically binding four kinds of serotype dengue virus |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0404097A2 (en) | 1989-06-22 | 1990-12-27 | BEHRINGWERKE Aktiengesellschaft | Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5169939A (en) | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5643759A (en) | 1993-10-30 | 1997-07-01 | Biotest Pharma Gmbh | Method for preparing bispecific monoclonal antibodies |
US5750078A (en) | 1991-09-18 | 1998-05-12 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing humanized chimera antibody |
US6020153A (en) | 1988-01-05 | 2000-02-01 | Ciba-Geigy Corporation | Chimeric antibodies |
US6420113B1 (en) | 1997-04-04 | 2002-07-16 | Biosite Diagnostics, Inc. | Chimeric polyclonal antibodies |
US6423511B1 (en) | 1992-09-07 | 2002-07-23 | Kyowa Hakko Kogyo Co., Ltd. | Humanized antibodies |
US6632927B2 (en) | 1989-12-21 | 2003-10-14 | Celltech Therapeutics Limited | Humanized antibodies |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004215125B2 (en) * | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
CN101466828B (en) * | 2006-04-13 | 2011-12-21 | 株式会社医学生物学研究所 | Fusion partner cells |
EP2144931A2 (en) * | 2007-04-04 | 2010-01-20 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Monoclonal antibodies against dengue and other viruses with deletion in fc region |
CA2739551C (en) * | 2008-10-13 | 2019-03-05 | Institute For Research In Biomedicine | Dengue virus neutralizing antibodies and uses thereof |
CN102264896B (en) * | 2008-12-25 | 2014-02-26 | 国立大学法人大阪大学 | Human anti-human influenza virus antibody |
WO2010093335A1 (en) * | 2009-02-10 | 2010-08-19 | Nanyang Technological University | Antibodies for diagnosis and treatment of flaviviral infections |
-
2012
- 2012-09-07 AU AU2012305807A patent/AU2012305807B2/en active Active
- 2012-09-07 MY MYPI2014700529A patent/MY170725A/en unknown
- 2012-09-07 WO PCT/JP2012/005699 patent/WO2013035345A2/en active Application Filing
- 2012-09-07 SG SG11201400100SA patent/SG11201400100SA/en unknown
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5169939A (en) | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
US6020153A (en) | 1988-01-05 | 2000-02-01 | Ciba-Geigy Corporation | Chimeric antibodies |
EP0404097A2 (en) | 1989-06-22 | 1990-12-27 | BEHRINGWERKE Aktiengesellschaft | Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US6632927B2 (en) | 1989-12-21 | 2003-10-14 | Celltech Therapeutics Limited | Humanized antibodies |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
US5750078A (en) | 1991-09-18 | 1998-05-12 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing humanized chimera antibody |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
US6423511B1 (en) | 1992-09-07 | 2002-07-23 | Kyowa Hakko Kogyo Co., Ltd. | Humanized antibodies |
WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5643759A (en) | 1993-10-30 | 1997-07-01 | Biotest Pharma Gmbh | Method for preparing bispecific monoclonal antibodies |
US6420113B1 (en) | 1997-04-04 | 2002-07-16 | Biosite Diagnostics, Inc. | Chimeric polyclonal antibodies |
Non-Patent Citations (144)
Title |
---|
"Remington's Pharmaceutical Sciences, 18th ed.,", 1990, MACK PUBLISHING CO. |
ALWIS ET AL., PLOS NTG, vol. 5, 2011, pages 188 |
BANKER AND CHALMERS: "Pharmaceutics and Pharmacy Practice", 1982, J. B. LIPPINCOTT COMPANY, pages: 238250 |
BELTRAMELLO ET AL., CELL HOST MICROBE, vol. 8, 2010, pages 271 - 283 |
BELTRAMELLO ET AL., CELL. HOST. MICROBE, vol. 8, 2010, pages 271 - 283 |
BELTRAMELLO M; WILLIAMS KL; SIMMONS CP; MACAGNO A; SIMONELLI L; QUYEN NT; SUKUPOLVI-PETTY S; NAVARRO-SANCHEZ E; YOUNG PR; DE SILVA: "The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity", CELL HOST MICROBE, vol. 8, 2010, pages 271 - 283, XP055071759, DOI: doi:10.1016/j.chom.2010.08.007 |
BERNARDO ET AL., CLIN VACCINE IMMUNOL, vol. 16, 2009, pages 1829 - 1831 |
BERNARDO L; FLEITAS O; PAVON A; HERMIDA L; GUILLEN G; GUZMAN MG: "Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strain with different genotypes", CLIN VACCINE IMMUNOL, vol. 16, 2009, pages 1829 - 1831, XP055112354, DOI: doi:10.1128/CVI.00191-09 |
BETTRAMELLO ET AL., CELL. HOST. MICROBE, vol. 8, 2010, pages 271 - 283 |
BOLHUIS ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 34, 1991, pages 1 - 8 |
BRACIALE TJ; HAHN YS; BURTON DR: "Fields Virology", 2006, LIPPINCOTT WILLIAMS & WILKINS, article "The adaptive immune response to viruses", pages: 279 - 325 |
CALISHER CH; KARABATSOS N; DALRYMPLE JM; SHOPE RE; PORTERFIELD JS; WESTAWAY EG; BRANDT WE: "Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera", J GEN VIROL, vol. 70, 1989, pages 37 - 43 |
CALISHER ET AL., J. GEN. VIROL., vol. 70, 1989, pages 37 - 43 |
CARTER ET AL., J. HEMATOTHERAPY, vol. 4, 1995, pages 463 - 470 |
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 878 - 883 |
CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
DE ALWIS ET AL., PLOS NEGL TROP DIS, vol. 5, 2011, pages E1188 |
DE ALWIS R; BELTRAMELLO M; MESSER WB; SUKUPOLVI-PETTY S; WAHALA WMPB; KRAUS A; OLIVAREZ NP; PHAM Q; BRIAN J; TSAI W-Y: "In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection", PLOS NEGL TROP DIS, vol. 5, 2011, pages E1188 |
DE ALWIS R; BELTRAMELLO M; MESSER WB; SUKUPOLVI-PETTY S; WAHALA WMPB; KRAUS A; OLIVAREZ NP; PHAM Q; BRIAN J; TSAI W-Y: "In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection", PLOS NTG, vol. 5, 2011, pages E 1188 |
DE ALWIS R; SMITH SA; OLIVAREZ NP; MESSER WB; HUYNH JP; WAHALA WMPB; WHITE LJ; DIAMOND MS; BARIC RS; CROWE JE, JR: "Identification of human neutralizing antibodies that bind to complex epitope on dengue virions", PROC NATL ACAD SCI USA, vol. 109, 2012, pages 7439 - 7444, XP055171295, DOI: doi:10.1073/pnas.1200566109 |
DEJNIRATTISAI ET AL., SCIENCE, vol. 328, 2010, pages 745 - 748 |
DEJNIRATTISAI W; JUMNAINSONG A; ONSIRISAKUL N; FITTON P; VASANAWATHANA S; LIMPITIKUL W; PUTTIKHUNT C; EDWARDS C; DUANGCHINDA T; SU: "Cross-reacting antibodies enhance dengue virus infection in humans", SCIENCE, vol. 328, 2010, pages 745 - 748 |
DIAMOND ET AL., IMMUNOL. REV., vol. 225, 2008, pages 212 - 225 |
DIAMOND MS; PIERSON TC; FREMONT DH: "The structural immunology of antibody protection against West Nile virus", IMMUNOL REV, vol. 225, 2008, pages 212 - 225 |
EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 3688 |
FALCONAR AKI: "Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins", ARCH VIROL, vol. 144, 1999, pages 2313 - 2330, XP055052767, DOI: doi:10.1007/s007050050646 |
FALCONAR ET AL., ARCH VIROL, vol. 144, 1999, pages 2313 - 2330 |
FINGL: "The Pharmacological Basis of Therapeutics", 1975, pages: I |
FRANK AL; SIX HR; MARCHINI A: "Human monoclonal antibodies to influenza virus: IgG subclass and light chain distribution", VIRAL IMMUNOL, vol. 2, 1989, pages 31 - 36, XP001010175 |
FRANK ET AL., VIRAL IMMUNOL., vol. 2, 1989, pages 31 - 36 |
FROGEL ET AL., J. MANAG. CARE PHARM., vol. 16, 2010, pages 46 - 58 |
FROGEL MP; STEWART DL; HOOPES M; FEMANDES AW; MAHADEVIA PJ: "A systematic review of compliance with Pilivizumab administration for RSV immuno- prophylaxis", J MANAG CARE PHARM, vol. 16, 2010, pages 46 - 58 |
GABIZON ET AL., J. NATIONAL CANCER INST., vol. 81, no. 19, 1989, pages 1484 |
GARCIA G; SIERRA B; PEREZ AB; AGUIRRE E; ROSADO I; GONZALEZ N; IZQUIERDO A; PUPO M; DIAZ DRD; SANCHEZ L: "Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the Fc RIIa polymorphism", AM J TROP MED HYG, vol. 82, 2010, pages 1153 - 1156 |
GODING: "Monoclonal Antibodies, Principles and Practice(2d ed.)", 1986, ACADEMIC PRESS |
GONCALVEZ AP; MEN R; WEMLY C; PURCELL RH; LAI CJ: "Chimpanzee Fab fragments and a derived humanized immunoglobulin G 1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses", J VIROL, vol. 78, 2004, pages 12910 - 12918, XP002338601, DOI: doi:10.1128/JVI.78.23.12910-12918.2004 |
GONCALVEZ ET AL., J. VIROL., vol. 78, 2004, pages 12910 - 12918 |
GREEN ET AL., J. IMMUNOL. METHODS, vol. 231, 1999, pages 11 - 23 |
GREEN LL: "Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies", J IMMUNOL METHODS, vol. 231, 1999, pages 11 - 23, XP004187631, DOI: doi:10.1016/S0022-1759(99)00137-4 |
HALSTEAD ET AL., J. EXP. MED., vol. 146, 1977, pages 201 - 217 |
HALSTEAD SB: "Dengue virus-mosquito interactions", ANNU REV ENTOMOL, vol. 53, 2008, pages 273 - 291 |
HALSTEAD SB; O'ROURKE EJ: "Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody", J EXP MED, vol. 146, 1977, pages 201 - 217 |
HALSTEAD, ANNU. REV. ENTOMOL., vol. 53, 2008, pages 273 - 291 |
HARLOW; LANE: "Antibodies, A Laboratory Manual", 1988, COLD SPRING HARBOR PRESS |
HARRIS E; VIDEA E; PEREZ L; SANDOVAL E; TELLEZ Y; PEREZ ML; CUADRA R; ROCHA J; IDIAQUEZ W; ALONSO RE: "Clinical, epidemiologic, and virologic features of dengue in the 1998 epidemic in Nicaragua", AM J TROP MED HYG, vol. 63, 2000, pages 5 - 11 |
HARRIS ET AL., AM. J. TROP. MED. HYG., vol. 63, 2000, pages 5 - 11 |
HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448 |
HWANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4030 |
INNIS BL; THIRAWUTH V; HEMACHUDHA C: "Identification of continuous epitopes of the envelope glycoprotein of dengue type 2 virus", AM J TROP MED HYG, vol. 40, 1989, pages 676 - 687 |
INNIS ET AL., AM. J. TROP. MED. HYG., vol. 40, 1989, pages 676 - 687 |
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525 |
JONES PT; DEAR PH; FOOTE J; NEUBERGER MS; WINTER G: "Replacing the complementarity-determining regions in a human antibody with those from a mouse", NATURE, vol. 321, 1986, pages 522 - 525 |
KARPAS A; DREMUCHEVA A; CZEPULKOWSKI BH: "A human myeloma cell line suitable for the generation of human monoclonal antibodies", PROC NATL ACAD SCI USA, vol. 98, 1998, pages 1799 - 1804, XP002179323, DOI: doi:10.1073/pnas.98.4.1799 |
KARPAS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 98, 1998, pages 1799 - 1804 |
KLASSEN CD: "Pharmacological Basis of Therapeutics", 1991, MCGRAW-HILL, article "Principles of Toxicology", pages: 49 - 61 |
KLASSEN CD: "Principles of Toxicology. In Pharmacological Basis of Therapeutics", 1991, MCGRAW-HILL, pages: 49 - 61 |
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 |
KOZBOR D; LAGARDE AE; RODER JC: "Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines", PROC NATL ACAD SCI USA, vol. 79, 1982, pages 6651 - 6655, XP001345428 |
KOZBOR D; RODER JC: "Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique", J IMMUNOL, vol. 127, 1981, pages 1275 - 1280, XP002009598 |
KOZBOR ET AL., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 6651 - 6655 |
KOZBOR, J. IMMUNOL., vol. 127, 1981, pages 1275 - 1280 |
KUBOTA-KOKETSU ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 387, 2009, pages 180 - 185 |
KUBOTA-KOKETSU ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 387, 2009, pages 180 - 185 |
KUBOTA-KOKETSU R; MIZUTA H; OSHITA M; IDENO S; YUNOKI M; KUHARA M; YAMAMOTO N; OKUNO Y; IKUTA K: "Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors", BIOCHEM BIOPHYS RES COMMUN, vol. 387, 2009, pages 180 - 185, XP026378974, DOI: doi:10.1016/j.bbrc.2009.06.151 |
KUHN RJ; ZHANG W; ROSSMANN MG; PLATNEV SV; CORVER J; LENCHES E; JONES CT; MUKHOPADHYAY S; CHIPMAN PR; STRAUSE EG: "Structure of dengue virus: implications for flavivirus organization, maturation, and fusion", CELL, vol. 108, 2002, pages 717 - 725 |
KUROSU ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 362, 2007, pages 1051 - 1056 |
KUROSU ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 394, 2010, pages 398 - 404 |
KUROSU ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 394, 2010, pages 398 - 404 |
KUROSU T; CHAICHANA P; YAMATE M; ANANTAPREECHA S; IKUTA K: "Secreted complement regulatory protein clusterin interacts with dengue virus nonstructural protein 1", BIOCHEM BIOPHYS RES COMMUN, vol. 362, 2007, pages 1051 - 1056, XP022249552, DOI: doi:10.1016/j.bbrc.2007.08.137 |
KUROSU T; KHAMLERT C; PHANTHANAWIBOON S; IKUTA K; ANATAPREECHA S: "Highly efficient rescue of dengue virus using a co-culture system with mosquito/mammalian cells", BIOCHEM BIOPHYS RES COMMUN, vol. 394, 2010, pages 398 - 404, XP026988997, DOI: doi:10.1016/j.bbrc.2010.02.181 |
KUROSU T; KHAMLERT C; PHANTHANAWIBOON S; IKUTA KM ANATAPREECHA S: "Highly efficient rescue of dengue virus using a co-culture system with mosquito/mammalian cells", BIOCHEM BIOPHYS RES COMMUN, vol. 394, 2010, pages 398 - 404, XP026988997, DOI: doi:10.1016/j.bbrc.2010.02.181 |
LANZAVECCHIA A; CORTI D; SALLUSTO F: "Human monoclonal antibodies by immortalization of memory B cells", CURR OPIN BIOTECHNOL, vol. 18, 2007, pages 523 - 528, XP022409619, DOI: doi:10.1016/j.copbio.2007.10.011 |
LANZAVECCHIA ET AL., CURR. OPIN. BIOTECHNOL., vol. 18, 2007, pages 523 - 528 |
LEYENDECKERS ET AL., EUR J IMMUNOL, vol. 29, 1999, pages 1406 - 1417 |
LEYENDECKERS ET AL., EUR. J. IMMUNOL., vol. 29, 1999, pages 1406 - 1417 |
LEYENDECKERS H; ODENDAHL M; LOHNDORF A; IRSCH J; SPANGFORT M; MILTENYI S; HUNZELMANN N; ASSENMACHER M; RADBRUCH A; SCHMITZ J: "Correlation analysis between frequencies of circulating antigen-specific IgG-bearing memory B cells and serum titers of antigen-specific IgG", EUR J IMMUNOL, vol. 29, 1999, pages 1406 - 1417 |
MANSBACH ET AL., PEDIATR EMERG CARE, vol. 23, 2007, pages 362 - 367 |
MANSBACH J; KUNZ S; ACHOLONU U; CLARK S; CAMARGO CA JR: "Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis", PEDIATR EMERG CARE, vol. 23, 2007, pages 362 - 367 |
MARASCO ET AL., NAT BIOTECH, vol. 25, 2007, pages 1421 - 1434 |
MARASCO WA; SUI J: "The growth and potential of human antiviral monoclonal antibody therapeutics", NAT BIOTECH, vol. 25, 2007, pages 1421 - 1434, XP009093629, DOI: doi:10.1038/nbt1363 |
MARTIN ET AL., J. BIOL. CHEM., vol. 257, 1982, pages 286 - 288 |
MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554 |
MCCAFFERTY J; GRIFFITHS AD; WINTER G; CHISWELL DJ: "Phage antibodies: filamentous phage displaying antibody variable domains", NATURE, vol. 348, 1990, pages 552 - 554 |
NOVEL ANTICANCER DRUG PROTOCOLS, 2003, pages 297 - 321 |
OKUNO ET AL., BIKEN J, vol. 21, 1978, pages 137 - 147 |
OKUNO Y; IGARASHI A; FUKAI K: "Neutralization tests fro dengue and Japanese encephalitis viruses by the focus reduction method using peroxidase-anti-peroxidase staining", BIKEN J, vol. 21, 1978, pages 137 - 147 |
OLIPHANT ET AL., J VIROL, vol. 81, 2007, pages 11828 - 11839 |
OLIPHANT ET AL., J. VIROL., vol. 81, 2007, pages 11828 - 11839 |
OLIPHANT T; NYBAKKEN GE; AUSTIN SK; XU Q; BRAMSON J; LOEB M; THROSBY M; FREMONT DH; PIERSON TC; DIAMOND MS: "Induction of epitope-specific neutralizing antibodies against West Nile virus", J VIROL, vol. 81, 2007, pages 11828 - 11839, XP055155874, DOI: doi:10.1128/JVI.00643-07 |
OMATSU ET AL., J GEN VIROL, vol. 92, 2011, pages 2272 - 2280 |
OMATSU ET AL., J MED PRIMATOL, 2012 |
OMATSU T; MOI ML; HIRAYAMA T; TAKASAKI T; NAKAMURA S; TAJIMA S; ITO M; YOSHIDA T; SAITO A; KATAKAI Y: "Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity", J GEN VIROL, vol. 92, 2011, pages 2272 - 2280 |
OMATSU T; MOI ML; TAKASAKI T; NAKAMURA S; KATAKAI Y; TANJIMA S; ITO M; YOSHIDA T; SAITO A; AKARI H: "Changes in hematological and serum biochemical parameters in common marmosets (Callithrix jacchus) after inoculation with dengue virus", J MED PRIMATOL, 2012 |
PAUL, W.,: "Fundamental Immunology, 2nd ed.", 1989, RAVEN PRESS |
PLUCKTHUN: "The Pharmacology of Monoclonal Antibodies", vol. 113, 1994, SPRINGER- VERLAG, pages: 269 - 315 |
PLUCKTHUN; PACK, IMMUNOTECHNOLOGY, vol. 3, 1997, pages 83 - 105 |
PUIPROM ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 413, 2011, pages 136 - 142 |
PUIPROM O; YAMASHITA A; SASAYAMA M; LIMKITTIKUL K; BOONHA K; JITTMITRAPHAP A; LEAUNGWUTIWONG P; KUROSU T; RAMASOOTA P; IKUTA K: "Co-existence of major and minor viral populations from two different origins in patients secondarily infected with dengue virus serotype 2 in Bangkok", BIOCHEM BIOPHYS RES COMMUN, vol. 413, 2011, pages 136 - 142, XP028294007, DOI: doi:10.1016/j.bbrc.2011.08.069 |
REICHERT ET AL., NAT. BIOTECHNOL., vol. 23, 2005, pages 1073 - 1078 |
REICHERT JM; ROSENSWEIG CJ; FADEN LB; DEWITZ MC: "Monoclonal antibody successes in the clinic", NAT BIOTECHNOL, vol. 23, 2005, pages 1073 - 1078, XP002555770, DOI: doi:10.1038/nbt0905-1073 |
REITER P, YELLOW FEVER AND DENGUE: A THREAT TO EUROPE EUROSURVEILL, vol. 15, 2010, pages 19509 |
RENNER; PFREUNDSCHUH, IMMUNOLOGICAL REVIEWS, no. 145, 1995, pages 179 - 209 |
SANGKAWIBHA ET AL., AM. J. EPIDEMIOL., vol. 120, 1984, pages 653 - 669 |
SANGKAWIBHA N; ROJANASUPHOT S; AHANDRIK S; VIRIYAPONGSE S; JATANASEN S; SALITUL V; PHANTHUMACHINDA B; HALSTEAD SB.: "Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak", AM J EPIDEMIOL, vol. 120, 1984, pages 653 - 669 |
SANGKAWIBHA N; ROJANASUPHOT S; AHANDRIK S; VIRIYAPONGSE S; JATANASEN S; SALITUL V; PHANTHUMACHINDA B; HALSTEAD SB: "Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong", AM J EPIDEMIOL, vol. 120, 1984, pages 653 - 669 |
SCHIEFFELIN ET AL., VIROL. J., vol. 7, 2010, pages 28 |
SCHIEFFELIN JS; COSTIN JM; NICHOLSON CO; ORGERON NM; FONTAINE KA; ISERN S; MICHAEL SF; ROBINSON JE: "Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient", VIROL J, vol. 7, 2010, pages 28, XP021069056 |
SCHMITTGEN ET AL., NAT PROTOC, vol. 3, 2008, pages 1101 - 1108 |
SCHMITTGEN TD; LIVAK KJ: "Analyzing real-time PCR data by the comparative C(T) method. comparative C(T) method", NAT PROTOC, vol. 3, 2008, pages 1101 - 1108, XP055137608, DOI: doi:10.1038/nprot.2008.73 |
SEGAL ET AL., IMMUNOBIOLOGY, vol. 185, 1992, pages 390 - 402 |
SEGAL ET AL., J. HEMATOTHERAPY, vol. 4, 1995, pages 377 - 382 |
SETTHAPRAMOTE C; SASAKI T; PUIPROM O; LIMKITTIKUL K; PITAKSAJJAKUL P; PIPATTANABOON C; SASAYAMA M; LEUANGWUTIWONG P; PHUMRATANAPRA: "Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection", BIOCHEM BIOPHY RES COMMUN, vol. 423, 2012, pages 867 - 872, XP028427449, DOI: doi:10.1016/j.bbrc.2012.06.057 |
SETTHAPRAMOTE ET AL., BIOCHEM BIOPHY RES COMMUN, vol. 423, 2012, pages 867 - 872 |
SHU ET AL., J CLIN MICROBIOL., vol. 41, 2003, pages 2408 - 2416 |
SHU PY; CHANG SF; KUO YC; YUEH YY; CHIEN LJ; SUE CL; LIN TH; HUANG JH: "Development of group- and serotype-specific one-step SYBR green 1-based real-time reverse transcription-PCR assay for dengue virus", J CLIN MICROBIOL., vol. 41, 2003, pages 2408 - 2416, XP009139730, DOI: doi:10.1128/JCM.41.6.2408?2416.2003 |
SIMMONS CP; BERNASCONI NL; SUGUITAN AL; MILLS K; WARD JM; CHAU NV; HIEN TT; SALLUSTO F; HA DO Q; FARRAR J: "Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N influenza", PLOS MED, vol. 4, 2007, pages E 178 |
SIMMONS CP; BERNASCONI NL; SUGUITAN AL; MILLS K; WARD JM; CHAU NV; HIEN TT; SALLUSTO F; HA DO Q; FARRAR J: "Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5Nl influenza", PLOS MED, vol. 4, 2007, pages E178, XP002593445 |
SIMMONS ET AL., PLOS MED, vol. 4, 2007, pages E178 |
SMITH SA; ZHOU Y; OLIVAREZ NP; BROADWATER AH; DE SILVA AM; CROWE JE, JR: "Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection", J VIROL, vol. 86, 2012, pages 2665 - 2675 |
STEINITZ ET AL., J. IMMUNOL., vol. 141, 1988, pages 3516 - 3522 |
STEINITZ M; TAMIR S; FRODIN JE; LEFVERT AK; MELLSTEDT H: "Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies", J IMMUNOL, vol. 141, 1988, pages 3516 - 3522 |
SUKUPOLVI-PETTY ET AL., J VIROL, vol. 84, 2010, pages 9227 - 9239 |
SUKUPOLVI-PETTY ET AL., J. VIROL., vol. 84, 2010, pages 9227 - 9239 |
SUKUPOLVI-PETTY S; AUSTIN SK; ENGLE M; BRIEN JD; DOWD KA; WILLIAMS KL; JOHNSON S; RICO-HESSE R; HARRIS E; PIERSON TC: "Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2", J VIROL, vol. 84, 2010, pages 9227 - 9239, XP055206127, DOI: doi:10.1128/JVI.01087-10 |
SUKUPOLVI-PETTY S; AUSTIN SK; ENGLE M; BRIEN JD; DOWD KA; WILLIAMS KL; JOHNSON S; ROCO-HESSE R; HARRIS E; PIERSON TC: "Structural and function analysis of therapeutic monoclonal antibodies against dengue virus type", J VIROL, vol. 84, 2010, pages 9227 - 9239, XP055206127, DOI: doi:10.1128/JVI.01087-10 |
TEICHER: "Assays for In Vitro and In Vivo Synergy", METHODS IN MOLECULAR MEDICINE, vol. 85 |
TEOH EP; KUKKARO P; TEO EW; LIM AP; TAN TT; YIP A; SCHUL W; AUNG M; KOSTYUCHENKO VA; LEO YS: "The structural basis for serotype-specific neutralization of dengue virus by a human antibody", SCI TM 4, vol. 139RA83, 2012 |
TOISSEL: "ASHP Handbook on Injectable Drugs, 4th ed.", 1986, pages: 622 630 |
TRAGGIAI E; BECKER S; SUBBARAO K; KOLESNIKOVA L; UEMATSU Y; GISMONDO MR; MURPHY BR; RAPPUOLI R; LANZAVECCHIA A: "An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus", NAT MED, vol. 10, 2004, pages 871 - 875, XP002385893 |
TRAGGIAI ET AL., NAT MED, vol. 10, 2004, pages 871 - 875 |
VAN DER SCHAAR HM; WILSCHUT JC; SMIT JM: "Role of antibodies in controlling dengue virus infection", IMMUNOBIOLOGY, vol. 214, 2009, pages 613 - 629, XP026170756, DOI: doi:10.1016/j.imbio.2008.11.008 |
VITETTA ET AL., SCIENCE, vol. 238, 1987, pages 1098 |
WAHALA ET AL., VIROLOGY, vol. 392, 2009, pages 103 - 113 |
WAHALA WMPB; KRAUS AA; HAYMORE LB; ACCAVITTI-LOPER MA; DE SILVA AM: "Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody", VIROLOGY, vol. 392, 2009, pages 103 - 113, XP026541913, DOI: doi:10.1016/j.virol.2009.06.037 |
WRAMMERT ET AL., NATURE, vol. 453, 2008, pages 667 - 671 |
WRAMMERT J; SMITH K; MILLER J; LANGLEY WA; KOKKO K; LARSEN C; ZHENG N-Y; MAYS I; GARMAN L; HELMS C: "Rapid cloning of high-affinity human monoclonal antibodies against influenza virus", NATURE, vol. 453, 2008, pages 667 - 671, XP002524388, DOI: doi:10.1038/NATURE06890 |
WRAMMERT J; SMITH K; MILLER J; LANGLEY WA; KOKKO K; LARSEN C; ZHENG N-Y; MAYSI; GARMAN L; HELMS C: "Rapid cloning of high-affinity human monoclonal antibodies against influenza virus", NATURE, vol. 453, 2008, pages 667 - 671, XP002524388, DOI: doi:10.1038/NATURE06890 |
YENCHITSOMANUS ET AL., SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH, vol. 27, 1996, pages 228 - 236 |
YENCHITSOMANUS ET AL., SOUTHEAST ASIAN J. TROP. MED. PUBLIC HEALTH, vol. 27, 1996, pages 228 - 236 |
YENCHITSOMANUS P; SRICHAROEN P; JARUTHASANA I; PATTANAKITSAKUL S; NITAYAPHAN S; MONGKOLSAPAYA J; MALASIT P: "Rapid detection and identification of dengue viruses by polymerase chain reaction (PCR", SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH, vol. 27, 1996, pages 228 - 236 |
ZAPATA ET AL., PROTEIN ENG., vol. 8, no. 10, 1995, pages 1057 - 1062 |
ZOMPI ET AL., VIRUSES, vol. 4, 2012, pages 62 - 82 |
ZOMPI S; HARRIS E: "Animal models of dengue virus infection", VIRUSES, vol. 4, 2012, pages 62 - 82 |
ZOU G; KUKKARO P; LOK S-M; NG JKW; TAN GK; HANSON BJ; ALONSO S; MACARY PA; SHI P-Y: "Resistance analysis of an antibody that selectively inhibits dengue virus serotype-1", ANTIVIRAL RES, vol. 95, 2012, pages 216 - 223, XP055112152, DOI: doi:10.1016/j.antiviral.2012.06.010 |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017512209A (en) * | 2014-02-11 | 2017-05-18 | ビステラ, インコーポレイテッド | Antibody molecules against dengue virus and uses thereof |
US9212217B2 (en) | 2014-02-11 | 2015-12-15 | Visterra, Inc. | Antibody molecules to dengue virus and uses thereof |
WO2015122995A1 (en) | 2014-02-11 | 2015-08-20 | Visterra, Inc. | Antibody moleules to dengue virus and uses thereof |
US10155806B2 (en) | 2014-02-11 | 2018-12-18 | Visterra, Inc. | Antibody molecules to dengue virus and uses thereof |
US9365639B2 (en) | 2014-02-11 | 2016-06-14 | Visterra, Inc. | Antibody molecules to dengue virus and uses thereof |
KR20160117608A (en) * | 2014-02-11 | 2016-10-10 | 비스테라, 인크. | Antibody molecules to dengue virus and uses thereof |
CN106211773A (en) * | 2014-02-11 | 2016-12-07 | 威特拉公司 | Antibody molecule and application thereof for dengue virus |
EP4047015A1 (en) | 2014-02-11 | 2022-08-24 | Visterra, Inc. | Antibody molecules to dengue virus and uses thereof |
KR102356951B1 (en) | 2014-02-11 | 2022-01-27 | 비스테라, 인크. | Antibody molecules to dengue virus and uses thereof |
US11059883B2 (en) | 2014-02-11 | 2021-07-13 | Visterra, Inc. | Antibody molecules to dengue virus and uses thereof |
CN105137068A (en) * | 2015-07-24 | 2015-12-09 | 烟台昊清生物科技有限公司 | Florfenicol on-site test paper, and preparation and use methods thereof |
CN105004860A (en) * | 2015-07-24 | 2015-10-28 | 烟台昊清生物科技有限公司 | Florfenicol rapid detection kit and preparation and use method thereof |
CN105137068B (en) * | 2015-07-24 | 2017-03-01 | 鲁东大学 | Florfenicol Site Detection reagent paper and its preparation, using method |
US11918651B2 (en) | 2016-03-25 | 2024-03-05 | Visterra, Inc. | Formulations of antibody molecules to dengue virus |
WO2017165736A1 (en) | 2016-03-25 | 2017-09-28 | Visterra, Inc. | Formulation of antibody molecules to dengue virus |
CN109929033A (en) * | 2019-03-15 | 2019-06-25 | 中国人民解放军军事科学院军事医学研究院 | A kind of human antibody specifically binding four kinds of serotype dengue virus |
CN109929033B (en) * | 2019-03-15 | 2020-06-02 | 中国人民解放军军事科学院军事医学研究院 | Human antibody specifically binding to four serotype dengue viruses |
WO2020186687A1 (en) * | 2019-03-15 | 2020-09-24 | 中国人民解放军军事科学院军事医学研究院 | Human antibody specifically binding four serotypes of dengue viruses |
Also Published As
Publication number | Publication date |
---|---|
MY170725A (en) | 2019-08-27 |
SG11201400100SA (en) | 2014-06-27 |
WO2013035345A3 (en) | 2013-09-06 |
AU2012305807A1 (en) | 2014-02-20 |
AU2012305807A8 (en) | 2014-03-13 |
AU2012305807B2 (en) | 2015-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11912757B2 (en) | Antibodies specifically binding to Zika virus epitopes and uses thereof | |
US9181328B2 (en) | Human monoclonal antibodies broadly protective against influenza B virus and methods of using the same | |
US7750123B2 (en) | Antibodies against SARS-CoV and methods of use thereof | |
WO2017181098A2 (en) | Antibody molecules to zika virus and uses thereof | |
US8637035B2 (en) | Anti-dengue virus antibodies | |
TW201815821A (en) | Anti-zika virus antibodies and methods of use | |
US11834494B2 (en) | Antibodies to zika virus and methods of use thereof | |
US20220306729A1 (en) | Neutralizing antibodies that bind to the zika virus domain iii envelope region | |
CA2731686A1 (en) | Neutralizing anti-influenza a virus antibodies and uses thereof | |
AU2012305807B2 (en) | Dengue-virus serotype neutralizing antibodies | |
US11479598B2 (en) | Anti-yellow fever antibodies, and methods of their generation and use | |
BR112020000619A2 (en) | multispecific antibodies that specifically bind to epitopes of the Zika virus and uses thereof | |
US9273121B2 (en) | Humanized monoclonal antibodies that specifically bind and/or neutralize Japanese encephalitis virus (JEV) and their use | |
JP7463366B2 (en) | Novel anti-Zika virus antibodies and uses thereof | |
US20210054055A1 (en) | Highly specific zika neutralizing human antibodies | |
WO2014064943A1 (en) | Antigenic peptide derived from dengue virus | |
WO2014034127A1 (en) | Binding/neutralizing human monoclonal antibodies against botulinum neurotoxin type b | |
US20090104207A1 (en) | Hepatitis C Virus Neutralizing Antibodies | |
US20220315646A1 (en) | Zika antibodies and their use | |
US20160264648A1 (en) | Antibody having broad neutralization activity against group 1 influenza a viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12780548 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2012305807 Country of ref document: AU Date of ref document: 20120907 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12014500544 Country of ref document: PH |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12780548 Country of ref document: EP Kind code of ref document: A2 |